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Abstract
Enteral nutrition with eicosapentaenoic acid (EPA; 20:5 n-3) and γ-linolenic acid
(GLA; 18:3 n-6) decreased pulmonary inflammation by reducing neutrophil
counts and chemotactic factors in bronchoalveolar lavage fluid during acute
respiratory distress syndrome (ARDS). We hypothesize that the antiinflammatory effects of EPA and GLA may be due, in part, to induction of
neutrophil apoptosis. Neutrophil apoptosis is an important physiological process
in the resolution of pulmonary inflammation. Furthermore, pro-inflammatory
eicosanoids formed from arachidonic acid (AA) by lipoxygenase (LO) and
cyclooxygenase (COX) pathways have been shown to inhibit apoptosis in certain
cell types. The purpose of this dissertation is to determine whether EPA and
GLA, alone or in combination, trigger apoptotic cell death in the human
promyelocytic leukemia HL-60 cell line. This dissertation will also determine
whether inhibition of LO and COX increases apoptosis with AA, the combination
of EPA and GLA, and EPA in HL-60 cells, in vitro. Finally, this dissertation will
determine the apoptotic gene profile of EPA/GLA-treated HL-60 cells.
Study 1, HL-60 cells were incubated with 10, 20, 50, and 100 µM EPA,
GLA or various combinations of EPA and GLA for 2, 4, 8, 12 and 24 hours. Oleic
acid (18:1 n-9) was used as a fatty acid control. Flow cytometry using dualstaining with propidium iodide and annexin V-FITC assessed apoptosis, necrosis
and viability. Apoptosis was verified by DNA fragmentation as assessed by
agarose gel electrophoresis. EPA, GLA, and various combinations of EPA and
GLA significantly induced apoptosis and reduced cell viability in HL-60 cells.
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Viability was significantly reduced to the same extent with the combination of 50
µM EPA\20 µM GLA as compared with 100 µM EPA. These data indicate that
EPA and GLA, alone or in combination, reduce cell survival by induction of
apoptosis. Thus, induction of apoptosis by select dietary n-3 (EPA) and n-6
(GLA) polyunsaturated fatty acids may be the mechanism of reduces pulmonary
inflammation in ARDS.
Study 2 was conducted as follows: HL-60 cells were incubated with 50 µM
AA and an enzyme inhibitor (1-10 µM) for either COX, LO, 12-LO, and 5-LO for
12 hours. Flow cytometry was used to assess viability, apoptosis, and necrosis.
Apoptosis was further assessed using TUNEL and DNA fragmentation. The
highest concentration of LO inhibitors, but not COX inhibitors, decreased viability
and increased apoptosis and necrosis in the presence of exogenous AA. These
results suggest that disruption of the metabolism of AA by LO, in particular 5-LO,
decreases cell survival and increases apoptosis. Thus, downstream metabolic
processing of AA by LO but not COX plays a critical role in the regulation of HL60 cell apoptosis.
Study 3 was conducted as follows: HL-60 cells were incubated with 50
µM EPA /20 µM GLA in the presence of an enzyme inhibitor (1-10 µM) for 12
hours. Compounds were used to inhibit COX (ibuprofen), 12-LO (baicalein), or
5-LO (AA-861). Flow cytometry assessed viability, apoptosis, and necrosis. 5LO inhibition reduced cell viability and increased cell death (apoptosis+necrosis)
in EPA/GLA-treated HL-60 cells. Inhibition of COX 1 and 2 and 12-LO had no
significant effect on cellular viability and death in EPA/GLA-treated HL-60 cells.
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Adding leukotriene B4 counteracted the effect of 5-LO inhibition on apoptosis in
EPA/GLA-treated HL-60 cells. These data suggest that the processing of EPA
and GLA by 5-LO is critical to HL-60 cell survival.
Study 4 was conducted as follows: HL-60 cells were incubated with 50
µM EPA in the presence of an enzyme inhibitor (1-10 µM) for 12 hours.
Compounds were used to inhibit either COX 1 and 2 (ibuprofen), 5-, 12-, 15-LO
(NDGA), 12-LO (baicalein), 5-LO (AA-861), and 5-LO activating protein (MK886). Eicosanoid (0.001-1.0 µM) add back experiments were also conducted;
LTB4 and 5-HETE with 5-LO inhibition and 12-HETE with 12-LO inhibition. Flow
cytometry, TUNEL assay, and caspase-3 western blotting were used to assess
apoptosis. Inhibition of COX 1 and 2 had no effect on apoptosis. Inhibition of 5LO and 12-LO significantly increased apoptosis in EPA-treated HL-60 cells.
Furthermore, addition of LTB4 reduced apoptosis to levels significantly lower than
EPA-treated HL-60 cells alone. 5-HETE and 12-HETE also lowered apoptosis to
control levels. These data indicate that inhibition of LO, particularly 5-LO,
increased apoptosis in EPA-treated HL-60 cells. Furthermore, this study clearly
demonstrated that the products of the LO enzymes, particularly LTB4, are critical
in the regulation of apoptosis in EPA-treated HL-60 cells.
Study 5 was conducted as follows: HL-60 cells were incubated with 50 µM
EPA and 20 µM GLA for 12 hours. Apoptotic gene profiles were assessed using
GEArray original series human apoptosis-2 gene arrays. Total RNA was
extracted and probes were synthesized with a primer mix unique for each array.
Arrays were hybridized and developed in a non-isotopic manner. Arrays were
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visualized using a 16-bit CCD camera. The apoptotic gene profile for no
treatment and EPA/GLA-treated HL-60 cells after 12-hours differed from each
other. When comparing density values as a percent of control, all genes
assayed were down-regulated. When comparing arrays’ relative intensities,
several genes were different between control and treatment groups. For
example, Bad, Bax, and Fas were down regulated and Bax, Bcl-2, and p53 were
up regulated as compared with control.
This dissertation has provided a possible mechanism for the observed
effect of EPA and GLA in human and animal studies of acute respiratory distress
syndrome (ARDS): i.e., that enteral nutrition with specialized diets containing
EPA and GLA reduced the number of neutrophils and reduced the levels of LTB4
in the bronchoalveolar lavage fluid, reduced pulmonary inflammation, and
improved clinical outcomes in patients and animals with ARDS. This dissertation
demonstrates that the observed clinical results may be due to increased
neutrophil apoptosis induced by EPA and GLA. Induction of apoptosis likely
occurs through a change in the eicosanoid profile as well a genetic change
through the up-regulation and down-regulation of various pro- and anti-apoptotic
genes. Thus, the ability to alter the inflammatory cell phospholipids profile to
reduce the amount of AA available for metabolism to pro-inflammatory
eicosanoids, in conjunction with 5-lipoxygenase inhibitory compounds, may lead
to new therapies that will increase neutrophil apoptosis and provide a injurylimiting pathway in the resolution of pulmonary inflammation in ARDS.
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3.5.1.

1

Part 1
Introduction

2
I. Introduction

There is strong evidence demonstrating that polyunsaturated fatty acids
(PUFA) from the n-3 series, as well as the combination of n-3 and n-6 series
PUFA, are beneficial in a variety of health problems such as cardiovascular
disease, arthritis, cancer, and pulmonary inflammation [1-4]. Certain dietary
PUFA have the ability to induce apoptosis in a variety of cell types. The
mechanism by which n-3 and n-6 PUFA induce beneficial effects may be through
induction of apoptosis of the effector cell, i.e. neutrophils in acute respiratory
distress syndrome.
Essential fatty acids are precursors of the eicosanoids, which play a
critical role in inflammatory cell function. Diets rich in arachidonic acid (AA, 20:4
n-6) lead to the formation of pro-inflammatory biological compounds. These proinflammatory eicosanoids play an essential role in the development of septic
shock, systemic inflammatory response syndrome, acute lung injury, and acute
respiratory distress syndrome (ARDS) [4]. Diets rich in eicosapentaenoic acid
(EPA, 20:5 n-3), found in fish oil, and γ-linolenic acid (GLA, 18:3 n-6), found in
borage, evening primrose, and blackcurrant seed oils, appears to attenuate some
of the pro-inflammatory effects of arachidonic acid [5-7].
Eicosapentaenoic acid is incorporated into and reduces the content of AA
in cell membrane phospholipids. Eicosapentaenoic acid is available for
enzymatic conversion to 3-series prostaglandins and 5-series leukotrienes [8].
These eicosanoids have anti-inflammatory properties and are considered less
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biologically active than the 2-series prostaglandins and 4-series leukotrienes
from AA [9]. γ-Linolenic acid is elongated to dihomo-γ-linolenic acid (DGLA),
which can be converted to prostaglandin E1 or 15-hydroxyeicosatetraenoic acid
(15-HETE), which has been shown to attenuate leukotriene B4 (LTB4) formation
by inhibiting 5-lipoxygenase [10]. Prostaglandin E1 has also been shown to
indirectly decrease leukotriene formation by the inhibition of 5-lipoxygenase [11].
The activation of neutrophils with lipopolysaccharide will prolong their survival in
vitro [12]. This effect can be blocked with LTB4 receptor antagonists, implying
that LTB4 plays a critical role in neutrophil viability. Leukotriene B4 also is a
potent recruiter of neutrophils to an inflamed site [13]. The ability to change the
eicosanoid profile from pro-inflammatory AA metabolites to less biologically
active EPA metabolites is beneficial in acute inflammatory conditions such as
ARDS.
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II. Rationale and Significance

Acute respiratory distress syndrome is an acute inflammatory process
characterized by neutrophil accumulation, increased pulmonary capillary
permeability, pulmonary edema, increased pulmonary vascular resistance, and
progressive hypoxemia [14;15], all of which have been attributed to the release
and metabolism of arachidonic acid to pro-inflammatory eicosanoids [16]. Diets
containing n-3 and n-6 PUFA, such as EPA and GLA, have been shown to
rapidly decrease the fatty acid concentration of arachidonic acid in cellular
phospholipids, thereby reducing the potential amount of arachidonic acid
available for metabolism [9;16;17]. Enteral nutrition with a diet containing EPA
and GLA reduces pulmonary inflammation and improves gas exchange and
clinical outcomes in patients with the ARDS [7]. The ability to attenuate
inflammation by dietary intervention has been of great interest since a nutritional
intervention is low risk to patients [16]. Our laboratory participated in a multicenter clinical study that showed that enteral nutrition with specialized diets
containing EPA and GLA reduced the number of neutrophils in the
bronchoalveolar lavage (BAL) fluid, reduced pulmonary inflammation, and
improved clinical outcomes of patients with ARDS [16]. Our laboratory has also
shown that diets containing EPA and GLA reduce the levels of leukotriene B4 in
the BAL fluid, as well as neutrophil accumulation in the lungs of endotoxic
animals on experimental diets compared with endotoxic animals on control diets
[9;18]. Thus, EPA and GLA have been shown to decrease lung microvascular
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permeability and improve oxygenation, cardiopulmonary function, and to reduce
pro-inflammatory eicosanoid synthesis in animal models of acute lung injury and
in human ARDS [9;16]. These improvements may be a direct result of fewer
neutrophils in the lung due to their reduced migration and/or increased clearance
by alveolar macrophages.
I hypothesize that the anti-inflammatory effects of EPA and GLA may be
due, in part, to induction of neutrophil apoptosis. I plan to use the human
promyelocytic HL-60 cell line as a model for human neutrophils in vitro. HL-60
cells share many functional characteristics with peripheral blood neutrophils,
such as containing azurophilic granules, and are, therefore, considered the
preferred immortalized cell line model for studying human neutrophil responses
in vitro [19;20]. Human neutrophils are short lived and will undergo apoptosis in
6-12 hours in vitro. HL-60 cells are an immortal cell line and do not
spontaneously undergo apoptosis at an accelerated rate. Thus, HL-60 cells are
a good substitute to measure the induction of apoptosis by fatty acids and are a
good model for peripheral blood neutrophils [19]. The significance of this work is
that elucidating if and how EPA and GLA are inducing apoptosis in HL-60 cells
may lead to new strategies to increase neutrophil apoptosis that may provide an
injury-limiting pathway in the resolution of inflammation such as that seen in
ARDS.
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III. Objectives

Objective 1: The primary goal of this dissertation is to determine the effect of
eicosapentaenoic acid, γ-linolenic acid, and the combination of eicosapentaenoic
and γ-linolenic acids on apoptosis in the human promyelocytic HL-60 cell line.
The results obtained may help to explain the results observed in the ARDS study
[16], as well as animal studies [9;18], in that there were fewer neutrophils and
lower levels of LTB4 in the bronchoalveolar lavage fluid of patients and animals
with ARDS on the experimental diet than in those patients and animals on a
control diet.

Objective 2: The second objective of this dissertation is to determine the effect of
inhibitors of the lipoxygenase and cyclooxygenase enzymes on apoptosis in
eicosapentaenoic acid, γ-linolenic acid, the combination of eicosapentaenoic and
γ-linolenic acids, as well as arachidonic acid-treated HL-60 cells. The results
obtained will determine if the eicosanoids products of these fatty acids are
important in the regulation of apoptosis in HL-60 cells. Furthermore, the results
will determine which branches of the eicosanoid metabolic pathways may be
important in the regulation of apoptosis in HL-60 cells.

Objective 3: The objective of this dissertation is to determine the apoptotic gene
profile of HL-60 cells treated with the combination of eicosapentaenoic acid and
γ-linolenic acid. The results obtained will determine which apoptotic genes, both
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pro- and anti-apoptotic are involved in EPA/GLA induced HL-60 cell apoptosis.
Knowledge of these genes will allow the possible elucidation of the genetic
mechanism via EPA and GLA induce apoptosis in HL-60 cells.
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I. Acute Respiratory Distress Syndrome

Introduction to ARDS:
Acute respiratory distress syndrome (ARDS) was first described by Ashbaugh
and colleagues in 1967 [1]. ARDS has several synonyms including, but not
limited to: adult respiratory distress syndrome, shock lung, Da Nang lung, white
lung syndrome, and wet lung syndrome [2]. Acute lung injury has been defined
by the European-American Consensus Conference on ARDS to be a condition
involving three key components. First, impaired oxygenation as defined as a
ratio of partial pressure of arterial oxygen (PaO2) to the fraction of inspired
oxygen (FiO2) that is ≤ 300 mm Hg regardless of how much positive endexpiratory pressure (PEEP) is used to provide respiratory support. Second,
frontal chest radiograph detection of bilateral pulmonary infiltrates. Third, a
pulmonary artery occlusion pressure of ≤ 18 mm Hg [3]. The definition of ARDS
consists of the same three components except that the ratio of PaO2 to FiO2
must be less than 200 mm Hg regardless of PEEP [3;4]. When ARDS was first
described in 1967 the mortality rate exceeded 95% [2]. The incidence of ARDS
in the United States of America has been estimated at 150,000 cases per year
and as recently as 1995 mortality still exceeded 50% [4;5]. Since 1967, ARDS
has become recognized as a frequent cause of acute respiratory failure in both
medical and surgical patients [6].
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Etiology of ARDS:
Many disorders are associated with ARDS such as aspiration of gastrointestinal
fluid or near drowning, drug toxicity, inhalation injury such as oxygen toxicity,
smoke inhalation, hematologic disorders such as multiple transfusions, metabolic
disorders such as pancreatitis, and neurological disorders such as brain tumor
[2]. However, the most common disorders associated with ARDS are shock,
trauma, and infection, particularly pneumonia and sepsis [2].

Pathology of ARDS:
The pathology of ARDS can be broken down into 3 specific phases; exudative
phase, proliferative phase, and fibrotic phase [7-9]. The exudative phase
consists of edema and hemorrhage. This phase typically occurs during the first
week after the onset of respiratory failure [9]. Changes consisting of intraalveolar hemorrhage, capillary congestion, and interstitial and alveolar edema
can be detected via bright field microscopy [7;9-11]. Most of these changes
occur through endothelial cell activation [12]. The distinct histologic features of
this phase are the formation of eosinophilic hyaline membranes along the
alveolar duct [9;10;13]. Injury to the hyaline membranes and, more importantly,
the endothelial-epithelial barrier causes alveolar edema and increased cellular
debris in the alveoli [9]. Much of this debris comes from necrosis of type I
alveolar epithelial cells, which slough off, leaving only the basement membrane
[9;14-16]. Endothelial cell injury with cellular swelling, increased pinocytotic
vesicles, widening intercellular junctions, and disruption of the basement
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membrane are visible with electron microscopy [17]. Typically, large numbers of
neutrophils are present intracapillary. This is predominantly seen in diffuse
alveolar damage secondary to sepsis and trauma [9;15;18]. Damage to the
alveolar epithelial barrier allows interstitial fluid to flow freely into the alveolar
spaces [9]. Increases in intra-alveolar edema and hemorrhage cause an
increase in the diffusion distance. An increase in diffusion distance adversely
affects the PaO2/FiO2 ratio. Typically the diffusion distance of gasses averages
2.2 µm in thickness [19].
The proliferative phase of ARDS consists of organization and repair [9].
By the third day after the clinical onset of ARDS, type II alveolar epithelial cells
proliferate along alveolar septa in an attempt to cover the denuded basement
membrane [9;17]. By the tenth day, fibrosis is apparent [7]. Type II alveolar
epithelial cells manufacture surfactant and consist of 16% of the parenchymal
cells of a normal lung [19]. These cells have a surface area of roughly 183 µm2.
In contrast, type I alveolar epithelial cells, which are flat to accommodate a
proper diffusion distance of 2.2 µm, constitute only 8% of the parenchymal cells
of a normal lung but have a surface area of roughly 5098 µm2, or 28 times the
surface area of type II cells [19]. The fibrosis of the lung occurs when fibroblasts
and myofibroblasts proliferate and migrate through breaks in the alveolar
basement membrane into the intra-alveolar exudate [9]. The fibroblasts convert
the exudate into dense fibrous tissue by the deposition of collagen [9;20].
Therefore, the proliferation of type II cells and fibrosis of the lung transforms the
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lung into a noncompliant end-stage organ and becomes a limiting factor in the
survivability of ARDS [9].
The last phase of ARDS consists of end stage fibrosis and is known as the
fibrotic phase [9]. This phase occurs three to four weeks after the onset of the
clinical ARDS. It is characterized by widespread formation of collagenous tissue
by fibroblasts causing thickened alveolar septa [2;9]. Intimal thickening and
medial hypertrophy of the pulmonary arterioles also occurs during this phase
[17;21]. This fibrosis reduces lung compliance, thereby decreasing the tidal
volume and increasing the work of breathing, resulting in CO2 retention [22].

Inflammation in ARDS:
The pathophysiology of ARDS is driven by an aggressive inflammatory reaction
with the main players being neutrophils, macrophages, endothelial cells, and
multiple mediator cascades [17;22]. Initiation of inflammation results in an
increase in leukocyte production and rapid recruitment to the inflamed site [22].
Several of the mediator cascades that are activated during inflammation are the
production of free radicals, chemokines, cytokines, acute phase proteins,
complement, coagulation pathway components, and eicosanoids [23-25]. The
most important of the cytokines involved in the process of inflammation are tumor
necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and IL-8 [22]. TNF-α has
been shown to play an important role in the coagulation response [26;27]. TNF-α
levels are raised in the pulmonary microcirculation and bronchopulmonary
secretions of patients with ARDS [28;29]. IL-8 is a proven chemoatractant for
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neutrophils and IL-8 levels are raised in BAL fluid of patients who ultimately
develop ARDS [22;30]. Excess production of inflammatory mediators, such as
TNF-α and reactive oxygen species, by neutrophils has been observed in
patients with ARDS [31-34]. The major leukocyte found in the bronchoalveolar
lavage (BAL) fluid and histological specimens from patients with ARDS is the
neutrophil [35].

Endothelium in ARDS:
The vascular endothelium is important in initiating and perpetuating the
inflammatory response in ARDS [17]. Endothelial cell activation is a principal
mechanism in the pathophysiology of ARDS [28]. Activation of the endothelial
cells is defined as a change in phenotype or function that can be induced by
various stimuli, including thrombin, cytokines, and bacterial products [27;28].
Endothelial cells express surface receptors for the thrombin, von Willebrand
factor, intercellular adhesion molecule-1 (ICAM-1), and selectins following
exposure to an activating stimulus [17;36]. Endothelial cells thrombin receptors
bind thrombin, which regulates endothelial cell function [28]. Binding of thrombin
causes endothelial cells to have a pro-thrombotic phenotype and increases
endothelial cell permeability by producing gaps between adjacent endothelial
cells, which leads to microvascular dysfunction and intravascular coagulation
[12;17;28]. Von Willebrand factor is also released from stimulated endothelial
cells [37]. Increased levels of von Willebrand factor antigen have been detected
in patients with at-risk diagnoses for the development of ARDS [37]. ICAM-1 and
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selectins are important components of the neutrophil-endothelial cell interaction
[17]. These interactions lead to the sequestration of neutrophils within the
pulmonary vasculature and subsequent tissue damage [9;17;28]. ICAM-1
interacts with the CD11/CD18 adhesion molecules expressed on the surface of
neutrophils [37]. The expression of CD11/CD18 on neutrophils is up-regulated in
the presence of inflammatory cytokines such as IL-1 and TNF-α [37]. Selectins
are also up-regulated by inflammatory cytokines. E-selectin mediates endothelial
cell adhesion to a variety of leukocytes and is endothelial cell-specific [37]. Pselectin is expressed in the Weibel Palade bodies of the endothelium and in the
alpha granules of platelets [38]. P-selectin, expressed on the surface of
endothelial cells, binds to the sialyl Lewis X chain on the surface of neutrophils
[38]. Vasoactive substances, such as prostacyclin (PGI2), endothelins, and nitric
oxide, are also produced and released by the endothelium [17].

Macrophages in ARDS:
The macrophage plays a critical role in the development of inflammation in ARDS
[17;39]. The alveolar macrophage is a resident cell within the lung and
contributes greatly to the inflammatory response by releasing pro-inflammatory
compounds such as eicosanoids, cytokines, and platelet activating factor (PAF)
[17;39]. Macrophages release eicosanoids, implicated in the development of
ARDS, derived from the cyclooxygenase and lipoxygenase pathways upon
stimulation [39]. Macrophages are also responsible for removing apoptotic
neutrophils by recognizing externalized phosphatidylserine on apoptotic cell
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surfaces [40;41]. Alveolar macrophages also protect against local infection.
Macrophages from patients with ARDS have defective phagocytosis and
bacterial killing abilities [17]. These macrophage defects exacerbate the
deleterious effects of ARDS by increased risk of infection and decreased
clearance of neutrophils.

Neutrophils in ARDS:
Neutrophils account for less than 3% of total cells in BAL fluid from healthy
patients. Conversely, 85% of the total cell population is neutrophils in BAL fluid
from patients with ARDS [42]. Because of the neutrophils’ destructive potential,
they are thought to be the key player in the pathology of ARDS [43;44].
Neutrophils are attracted to an inflamed site by a variety of compounds, such as
bacterial factors, complement components, lymphokines, peptides,
immunoglobulin fragments, macrophage products, cell surface antigen-antibody
reactions, interleukines, and lipids including prostaglandins and leukotrienes
[33;45]. Neutrophils themselves are important sources of pro-inflammatory
compounds [17]. In order for neutrophils to cause tissue damage, they must first
migrate from the circulation to the target tissue area. Neutrophils change in both
biochemical and adhesive properties upon stimulation to facilitate their
movement [43]. Neutrophils diapedese and chemotax through a variety of
interactions. Neutrophils roll along the endothelium due to interaction with
selectins (e.g. L, P, E-selectin) and intracellular adhesions molecules (e.g. ICAM1) [17;43;46]. Blockage of L-selectin with a monoclonal antibody prevented
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neutrophil sequestration in alveolar capillaries in an endotoxemic rabbit model,
demonstrating the importance of L-selectin in neutrophil migration [47]. Once the
neutrophil has diapedesed, it is attracted to the inflamed site by a variety of proinflammatory compounds, such as leukotriene B4 and IL-8 [30;48;49].
Neutrophils have a potent mechanism for phagocytosing and killing microbes
[45]. Neutrophil pseudopodia engulf particles in a pouch of plasma membrane.
This process is facilitated by opsonization of the phagocytosed particle [45].
Once the microbe or particle has been phagocytosed, it is subjected to digestion
by potent enzymes and O2 free radicals [45].
Oxygen metabolite-mediated injury is the likely insult provided by
neutrophils in ARDS [50]. Both patients and animal with ARDS have increased
levels of oxidative stress, as exhibited by increased blood lipid peroxide levels,
increased exhalation of H2O2, and decreased blood and BAL glutathione levels
[44;50]. Plasma protein thiol levels are significantly lower in ARDS patients who
did not survive than in those who did, suggesting they suffer from severe
oxidative stress [51]. Metnitz et al, 1999 [52] demonstrated that the anti-oxidants
alpha-tocopherol, beta-caratene, selenium, and ascorbate were reduced in the
blood of patients with ARDS compared with healthy volunteer blood.
Additionally, plasma lipid peroxidation levels were significantly increased. The
production of oxygen radicals (.O2-, H2O2, .OH) by neutrophils is referred to as
oxygen or respiratory burst. This burst is associated with increased oxygen
consumption, hexose monophosphate shunt activity, and chemiluminescence
[45]. Many of the reactive oxygen species are most likely formed via the NADPH

21
oxidase complex [43]. Some of the most important mediators of neutrophil
chemotaxis, activation, and survival are metabolites of arachidonic acid, the
eicosanoids, particularly the leukotrienes and prostaglandins [49;53;54]. Thus,
the eicosanoids are critical in the pathology of ARDS.
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II. Eicosanoids and Essential Fatty Acids

Metabolism of Essential Fatty Acids:
Eicosanoids are 20 carbon fatty acid oxidized derivatives of essential fatty acids
[55]. There are two families of essential fatty acids, the n-3 or ω-3 and the n-6 or
ω-6. Certain fatty acids were found to be essential in 1929 by Burr and Burr [56].
They noted that rats eating a fat free diet developed a series of phenotypic
changes including a scaly condition of the skin, swollen and scaly tail, and the
tendency to lose hair from the face, back, and throat [56]. These fatty acids are
considered to be essential because the human body cannot produce them and
they must come from the diet [57]. The human body does not exhibit a
desaturase enzyme that can alter the structure of the fatty acid beyond the ninth
carbon from the carboxcylic end of the molecule. Thus, like any other essential
nutrient, without it, disease will follow.
The parent compounds of the n-3 and n-6 fatty acids are α-linolenic acid
(18:3 n-3) and linolenic acid (18:2 n-6), respectfully. These fatty acids can be
elongated and desaturated via a series of enzymes (Fig. 2.2.1). The same
enzymes metabolize both the n-3 and the n-6 fatty acids. The n-3 fatty acids can
be converted into eicosapentaenoic acid (EPA, 20:5 n-3) and the n-6 fatty acids
to arachidonic acid (AA, 20:4 n-6). It is important to note that fatty acids from the
different n-families are not interconvertible [58]. Fatty acids that are of interest in
this dissertation are EPA, AA, and γ-linolenic acid (GLA, 18:3 n-6). EPA is found
in fish oils, AA exclusively in animal products, and GLA in borage, evening
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Figure 2.2.1. The n-3 and n-6 families of fatty acids.

24
primrose, and blackcurrant seed oils [55;59;60]. Diets rich in AA lead to the
formation of pro-inflammatory compounds while diets rich in EPA and GLA
attenuate some of the pro-inflammatory effects of AA [55;61]. Pro-inflammatory
products from AA most likely play an essential role in the development of septic
shock, systemic inflammatory response syndrome, acute lung injury, and ARDS
[62].
Polyunsaturated fatty acids, such as EPA and AA, are typically stored in
the cell in the sn2 position of phospholipid membranes [63]. Newly ingested fatty
acids enter into the phospholipid pools through the constant process of lipid
remodeling occurring in the cell [63]. When a cell is stimulated, phospholipase
A2 (PLA2) clips the fatty acid out of the sn2 possition yielding a free fatty acid and
a lysophospholipid (Fig. 2.2.2.) [64]. This particular PLA2 is a calcium-dependent
phospholipase from the group IV family known as cPLA2 [64-66]. cPLA2 is
specific for PUFA, particularly AA in the sn2 position of the phospholipids [66].
Once the PUFA from the sn2 position has been released by cPLA2 it can be
further metabolized by cyclooxygenase, lipoxygenase, or cytochrome P450
enzymes.

Cyclooxygenases:
The cyclooxygenase pathway consists of two primary enzymes, ubiquitously
expressed prostaglandin H synthase-1 (PGH 1) or cyclooxygenase 1 (COX 1)
and inducible prostaglandin H synthase-2 (PGH 2) or cyclooxygenase 2 (COX 2)
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[67]. COX 1 is located on the luminal surface of the endoplasmic reticulum and
COX 2 is located on the luminal surface of the nuclear envelope [68]. There are,
however, conflicting reports as to where the isoforms are located. Several
studies state that COX 1 is equally distributed between the endoplasmic
reticulum and nuclear membrane, as well as that COX 1 and 2 are on both the
inner and outer nuclear membrane in certain cell types [67;69;70].
COX 1 gene location is on chromosome 9 and COX 2 gene location is on
chromosome 1. COX 1 gene is ~22 kb in length and does not contain a TATA
box. COX 2 gene is ~8 kb in length and does contain a TATA box, while COX 2
promoter is highly inducible [68]. COX 1 contains 11 exons and 10 introns while
COX 2 contains 10 exons and 9 introns [71]. COX 1 mRNA is 2.7 kb in size and
COX 2 mRNA is 4.5kb in size [71]. COX 2 mRNA is much less stable than COX
1 mRNA. COX 1 mRNA is found to be constitutively expressed in most tissues in
the body, while COX 2 mRNA is normally undetectable in most tissues [68]. The
most obvious differences in COX 1 and COX 2 gene products is that COX 1
contains a 17 amino acid sequence on its amino end that COX 2 does not
contain; and COX 2 contains an 18 amino acid sequence on its carboxyl end that
COX 1 does not [72]. COX 1 gene product contains 576 amino acids while COX
2 gene product contains 587 amino acids [73]. The active site of COX 1 is a
slightly different shape than the active site of COX 2 even though their crystalline
structures are super-imposable.
Each form of COX carries out distinct reactions. COX 1 is, as stated
before, constitutively expressed in many tissues. It is involved in cell-cell
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signaling and homeostasis. It is active at relatively low levels when compared
with COX 2. COX 2 is an inducible enzyme and is not normally present in
unstimulated cells (exceptions: brain, testes, kidney) [74]. COX 1 expression is
marginally affected by inflammatory stimuli while COX 2 expression is upregulated by inflammatory stimuli. Since these two isoforms react under different
cellular conditions, it is important that there are two forms. COX 1 has a Km
~20nm while COX 2 has a Km ~2nm for prostaglandin (PG) G2 as a substrate.
This means that COX 2 is activated with 1/10 the concentration needed to
activate COX 1. Since COX 2 is primarily involved with mitogenesis and
inflammation and is 10 times more responsive than COX 1, it would be harmful if
constitutively expressed. Therefore, COX 2 becomes important in cells under
some sort of duress (i.e., inflammation, mitogenesis).
The relative Km (µM) and Vmax (%) for COX 1 for arachidonic acid is
5.4µM and 105%, eicosatrienoic acid is 14µM and 74%, linoleic acid and is 12µM
and 11%, and α-linolenic acid is 200µM and 7.6% [75]. The relative Km (µM)
and Vmax (%) for COX 2 for arachidonic acid is 5.6µM and 106%, eicosatrienoic
acid is 28µM and 128%, linoleic acid and is 27µM and 76.2%, and α-linolenic
acid is 48µM and 74% [75]. γ-Linolenic acid and eicosapentaenoic acid are poor
substrates for both COX 1 and 2 [74;75]. However, both acids are better
substrates for COX 2 than for COX 1. Eicosapentaenoic acid is not converted to
PGH3 anywhere near as efficiently as arachidonic acid is converted to PGH2.
COX 1 and 2 metabolize AA to PGG2 and EPA to PGG3 [67]. PGG2 and
PGG3 are subsequently converted to PGH2 and PGH3, respectively, by the
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peroxidase reaction of the COX enzyme [68;74]. PGH2 can then be converted to
a host of prostaglandins including PGI2 (prostacylcin), PGE2, and thromboxanes
(TX) A2 (Fig. 2.2.3) [74]. Metabolites of PGH3 will be the same as PGH2 except
they have three double bonds instead of two and, subsequently, have the
subscript 3 (i.e. PGE3). PGH2 can ultimately be converted to form many products
including PGA2, PGB2, PGC2, PGD2, PGE2, PGF2α, and PGJ2 (Fig 2.2.4).
Prostaglandins derived from AA have been shown to be involved in the cardinal
signs of inflammation: pain, swelling, and fever [76]. Eicosanoids derived from
EPA counteract the responses of AA-derived eicosanoids [61]. TXA2 is a potent
platelet aggregator as well as a potent vasoconstrictor and bronchoconstictor
produced in larger quantities by platelets than other tissues [74]. Conversely,
TXA3, derived from EPA, is a very weak platelet aggregator and vasoconstrictor
[61;77]. PGI2 is a potent vasodilator of vascular smooth muscle cells as well as a
potent inhibitor of platelet aggregation [78]. PGI3, derived from EPA, is just as
biological active as AA-derived PGI2 [77]. PGE2 is one of the most proinflammatory prostaglandins. PGE2 increases vasodilatation, increases vascular
permeability, as well as modulates fever and pain [77]. PGE3 is a weak
vasodilator of vascular smooth muscle cells. Furthermore, dietary EPA reduces
the levels of PGE2 in human subjects [59]. Anti-inflammatory compounds can
also be formed when GLA is metabolized by COX. GLA is rapidly elongated to
dihomo-γ-linolenic acid (DGLA), which is metabolized by COX to form the
monoenoic prostaglandins (PGE1) [62]. PGE1 is a potent vasodilator of
pulmonary and systemic circulation, as well as inhibiting platelet aggregation,
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Figure 2.2.3. Schematic of cyclooxygenase pathway of eicosanoid formation.
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neutrophil chemotaxis, oxygen free radical release, and phospholipase A2 activity
[57].
Recently, there has been the possible discovery of a third COX isoform,
COX 3. It is thought that COX 3 does not produce pro-inflammatory compounds
but produces anti-inflammatory compounds that are important in the resolution of
inflammation [79]. Furthermore, the lack of this isoform may result in chronic
inflammatory disorders such as rheumatoid arthritis [79]. COX 3 is made from
COX 1 mRNA that retains intron 1 [80]. The intron that is left from the COX 1
mRNA introduces 30-34 amino acids into the COX 3 protein [80]. COX 3 mRNA
is expressed in human cerebral cortex and heart as a 5.2 kb transcript [80]. COX
3 is selectively inhibited with various analgesic and anti-pyretic drugs such as
acetaminophen, phenacetin, dipyrone, and antipyrine [80]. COX 3 is an isoform
that is thought to explain why acetaminophen is an analgesic and anti-pyretic but
not an anti-inflammatory compound [81;82].

Lipoxygenases:
The lipoxygenases are a group of dioxygenase enzymes that incorporate
molecular oxygen into PUFA [83]. There are three groups of lipoxygenase (LO)
enzymes in humans, 5-, 12-, and 15-lipoxygenase. Specifically there are 5
identified human lipoxygenases; human reticulocyte-type 15(S)-LO, human
platelet-type 12(S)-LO, human 5(S)-LO, human epidermis-type 12(R)-LO, and
human epidermis-type 15(S)-LO [84;85]. The number of the LO referes to the
oxygenation site on a standard arachidonic acid molecule [83].

32
12-LO is a cytosolic protein that converts AA into12hydroperoxyeicosatetraenoic acid (12-HPETE) [74]. 12-LO translocates from the
cytosol to the membrane via a calcium-dependent mechanism as demonstrated
in human erythroleukemia cells [86]. However, It has been demonstrated that
12-LO is inactive at the membrane [87]. 12-LO will also convert EPA to 12hyrdoperoxyeicosapentaenoic acid (12-HPEPE). 12-HPETE is the starting
material for the formation of the hepoxilins and trioxilins (Fig. 2.2.5) and 12-LO
can also produce 15-HPETE under certain conditions [74;83]. 12-LO has also
been shown to possess LTA synthase activity [83].
Human 12-LO consists of roughly 662 amino acid residues and has a
molecular weight of roughly 75 kDa [83]. Human platelet-type 12-LO gene is
located on chromosome 17 and the gene is 17kb with 14 exons. This gene
contains a TATA-like box, as well as other transcriptional elements such as GC,
AP-2, and CACCC [88]. If Vmax is set at 100% for arachidonic acid, EPA has a
Vmax of 107%, 5-HETE 40%, 5-HPETE 3%, and 15-HPETE 2% [83]. Therefore,
EPA is a better substrate for 12-LO than is AA.
The hepoxilins act in the release of intracellular calcium and the opening
of potassium channels [83]. Hepoxilin A3 has been thought to act as second
messenger in blood platelets and neural cells [74]. Hepoxilin B3 activity remains
unknown [74]. The hepoxilins are short lived and rapidly hydrolyzed to form the
trioxilins [74]. 12-LO has been shown to be present in the skin of rats, and when
stimulated with bradykinin and platelet activating factor, both potent proinflammatory compounds, produced 12-HETE and hepoxilins [89]. Furthermore,
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12-HETE administered intradermally increased vascular permeability and acute
inflammation [89]. Much work still needs to be done to elucidate the function of
12-LO products because physiological and pathological roles of 12-LO have not
yet been established [83].
15-LO is a cytosolic protein that converts arachidonic acid in 15-HPETE
[90]. There have been two different human 15-LO identified; 15-LOa (formerly
called 12/15 LO or 15-LO1) and 15-LOb (formerly called 15-LO2) [91]. 15-LOa is
highly expressed in bronchial epithelial cells and eosinophils [91]. 15-LOb is
expressed in lung, skin, prostate, and hair roots [91]. There is evidence, such as
seen with 12-LO, that 15-LO can translocate to the membrane in the presence of
calcium [90]. 15-LO incorporates molecular oxygen at carbon 15 on arachidonic
acid [91]. 15-LO is equally receptive to metabolize linoleic acid and incorporate
molecular oxygen at carbon 13 [91]. 15-LO is not constitutively expressed in
most human cells [90].
Human 15-LO consists of 661 amino acids and codes for a protein with a
molecular weight of 75 kDa [90]. The 15-LO gene is located on chromosome 17
and has 14 exons and 13 introns [90]. This gene is very similar in size and
placement to the human 12-LO gene, implying that they are closely related and
recently diverged from each other on an evolutionary scale [90]. This gene has
several promoter motifs including a TATTTA box, GC box, NF-1 binding site and
a CCAAT element [90].
15-LOa metabolizes AA to form 15-HETE (Fig. 2.2.6) and LA to form 13hydroxyoctadecadienoic acid (13-HODE) (Fig. 2.2.7) [91]. 15-LOb converts AA
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to 15-HETE but does not convert LA to 13-HODE effectively [91]. 13-HODE is
involved in cellular signaling, such as when administered to fibroblasts, there is
enhanced epidermal growth factor production [74]. AA metabolites of 15-LO are
involved in inflammation and assist in the maturation of reticulocytes to
erythrocytes [74]. 15-LO products have anti-inflammatory properties. 15-HETE
inhibits leukotriene production by neutrophils as well as inhibits leukotriene B4induced chemotaxis of neutrophils and neutrophil migration across cytokine
activated endothelium [91].
5-LO is cytosolic and is expressed in high levels in PMNs, monocytes, and
macrophages [92]. Lower levels have been reported in tissues such as the brain
[74]. When a cell is stimulated, cytosolic 5-LO translocates to the nuclear
membrane [93]. There is recent evidence of a 5-LO that resides on the nuclear
envelope [94]. This 5-LO also translocates to the nuclear membrane upon
stimulation [93]. Once 5-LO has translocated to the nuclear membrane, it
interacts with five lipoxygenase activating protein (FLAP). FLAP is an 18 kDa
membrane-associated protein that is highly expressed in cells of myloid origin
[92;95]. FLAP is critical in fatty acid metabolism by 5-LO [92]. FLAP acts as a
transfer protein and delivers fatty acid released by cPLA2 to 5-LO for metabolism
[92].
The 5-LO amino acid sequence contains 672 or 673 amino acids and the
monomers’ molecular weight is between 72 and 80 kDa [96]. RNA from lung and
leukocytes is 2.7 kb in size [96]. The 5-LO gene is located on chromosome 10
and contains 14 exons [97]. 5-LO activity is considered calcium-dependent.
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However, evidence shows that there is some activity in the absence of calcium
[96]. 5-LO is at full activation when calcium concentrations are between 4-10 µM
[96].
5-LO metabolizes AA to form the 4-series leukotrienes and EPA to form
the 5-series leukotrienes (Fig. 2.2.8) [98]. Eicosanoids from the 5-series
leukotrienes are less biologically active than eicosanoids from the 4-series
leukotrienes [39]. LTA4 can go through LTA4 hydrolase and form LTB4. LTB4 can
be further modified by cytochrome P450 to produce 20-hydroxy-LTB4 which
again can be acted on by cytochrome P450 to form 20-carboxy-LTB4 [74]. LTA4
can also go through glutathione-S-transferase to produce LTC4. LTC4 can be
further modified by γ-glutamyl transpeptidase to form LTD4. Removal of the Gly
form LTD4 will create LTE4. LTF4 is created if the γ-Glu is placed back onto the
LTE4 [99]. Lipoxins are also derived from LTA4. LTA4 can be acted on by 12LOX which will form 5(6)-epoxytetraene; this can be attacked by a hydroxyl at
carbon 6 to produce lipoxin A4 or attacked at carbon 14 to produce lipoxin B4
[100]. 14,15-LTA4 can also go through these same steps to produce both lipoxin
A4 and B4 [101].
The cysteinyl leukotrienes, LTC4, LTD4, and LTE4, collectively were
originally referred to as slow-reacting substance of anaphylaxis [102]. Cysteinyl
leukotrienes have also been termed sulphido leukotrienes and peptidyl
leukotienes [103]. Cysteinyl leukotrienes mediate smooth muscle contraction
leading to vasoconstriction and bronchoconstriction [104]. They increase
capillary permeability leading to plasma leakage as well as increase mucus
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secretions [76;103]. The cysteinyl leukotrienes have also been implicated in
decreasing blood pressure by reducing myocardial contractility and coronary
blood flow, as well as causing the release of luteinizing hormone from rat anterior
pituitary cells [104].
LTB4 has been shown to be important in promoting neutrophil chemotaxis
and adhesion to vascular endothelium [76]. LTB4 has also been shown to
increase enzyme release, degranulation, and generation of superoxide in
neutrophils [103;104]. LTB4 mobilizes calcium pools and increases uptake of
extracellular calcium, increases intracellular cAMP levels, and increases vascular
permeability. LTB4 plays a critical role in neutrophil viability and chemotaxis
[49;54]. Recently, LTB4 has been shown to be very important in promoting cell
survival in vitro. Neutrophil survival was increased in the presence LPS. This
survival was reversed when LTB4 inhibitors were co-incubated with the
neutrophils [105]. Leukotrienes derived from EPA are far less pro-inflammatory
than are leukotrienes derived from AA. Furthermore, EPA derived leukotrienes
compete for binding sites with AA-derived leukotrienes [106]. It is apparent that
LTB4 is intimately involved in inflammation, while the cysteinyl leukotrienes are
intimately involved with allergy and asthma.
The formation of lipoxins occurs through the metabolism of multiple
lipoxygenases [74]. The lipoxins can be formed from three basic starting
materials: LTA4, 15(S)-HPETE, and 15(R)-HPETE as shown in figure 2.2.9. The
lipoxins are important in a variety of areas. The lipoxins will decease adhesion
and transmigration of neutrophils and act as counter-regulatory signals in the
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resolution of inflammation [107]. They inhibit neutrophil chemotaxis induced by
LTB4 and fLMP [100]. They inhibit the endothelial cell leukocyte interaction,
thereby reducing adhesion and transmigration [91]. Lipoxin A4 stimulates the
phagocytosis of apoptotic neutrophils by macrophages to aid in the resolution of
inflammation [109]. Lipoxin A4 has been shown to have spasmogenic activities.
It will cause contraction in guinea pig lung strips. However, it does not cause
contraction in the ileum of the guinea pig [104]. Lipoxin A4 can act at the LTC4LTD4 receptor as an agonist and inhibit LTD4, and induce inositol-1,4,5triphosphate (IP3) generation. Lipoxin A4 has been shown to activate protein
kinase C (PKC) and act as an intracellular signal [101]. The lipoxins may act as
immunoreglators, as well as be involved in wound healing; but, most importantly,
they are involved in the resolution of inflammation [107]. Lipoxin A5 and B5,
derived form EPA, are as biologically potent as AA-derived lipoxins A4 and B4
[110].
Aspirin already has a great anti-inflammatory ability just through its
inhibition of the COX enzymes. Charles Serhan has described a unique attribute
that aspirin has to further combat inflammation called aspirin-triggered lipoxins
[100;108]. When aspirin inhibits COX 1, it cannot make any products. However,
when aspirin inhibits COX 2, it will preferentially convert arachidonic acid to
15(R)-HETE instead of PGG2. 15(R)-HETE is then converted to 15-epi-lipoxins
(LX) via 5-LO (Fig. 2.2.9) [100]. 15-epi-LXA4 has been shown to inhibit the
recruitment of neutrophils to inflamed tissues. 15-epi-LXA4 has most of the same
biological activities as the other lipoxins previously discussed. Neutrophils are
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known to increase tissue damage and exacerbate the inflammatory response.
Neutrophils will create vascular injury; which, in turn, will lead to increased
vascular permeability, followed by edema, and recruitment of more neutrophils.
These neutrophils will, in turn, release more LTB4 and the vicious cycle will
continue. Serhan has demonstrated that inflammatory stimuli (e.g. LPS, fLMP)
will induce COX 2 to produce 15(R)-HETE when in the presence of aspirin [100].
The 15-(R)-HETE will be modified by neutrophils as described above to form the
aspirin-triggered lipoxins. The aspirin-triggered lipoxins will inhibit the movement
of the neutrophils, thereby limiting the tissue damage and resolving inflammation
[100;108].

Cytochrome P450:
Cytochrome P450 is a heme protein that participates in monooxgenase reactions
[111]. It is found in the smooth endoplasmic reticulum and mitochondria,
although most cytochromes are located in the mitochondria. It can react with O2
and carbon monoxide [112]. One can distinguish cytochrome P450 from other
cytochromes in that the carbon monoxide complex of the reduced form of
cytochrome P450 absorbs light at 450nm [112]. Hence, it was given the name
cytochrome P450.
Cytochrome P450 functions in four major areas: metabolism of fatty acids
and their derivatives, production of steroid hormones, inactivation or activation of
therapeutic drugs (“xenobiotic metabolism”), and conversion of chemicals to
highly reactive molecules [113]. There are a variety of different isoforms of

43
cytochrome P450s and their absorbance spectra range from 446-452nm. The
general reaction that is involved with cytochrome P450 involves NADPH and
molecular oxygen (NADPH + H+ + O2 + RH → NADP+ + H2O + ROH) [113].
Cytochrome P450 is the terminal electron acceptor in the electron transport
chain. Cytochrome P450 is involved in the formation of the epoxyeicosatrienoc
acids (EETs), the hydroxyeicosatetraenoic acids (HETEs), and ω oxidation
products from arachidonic acid [111]. During the formation of the EETs, an
epoxide ring is formed. This ring is unstable and breaks down to alcohols and
forms the dihydroxyeicosatrienoic acids (DHTs) [74]. All of the cytochrome P450
isoforms are capable of forming EETs. They all have regio-specificity and
preferred stereo-specificity [111]. The isoforms locations in the body are tissuespecific. For example, CYP2C is highly expressed in the liver and kidney while
CYP2J is highly expressed in the heart [113]. Many factors influence the
expression of the isoforms. Pentabarbital increases CYP2B expression, fasting
decreases CYP2C11 expression, and dietary salt increases CYP2C23
expression [111;113].
EETs are important mediators of endothelium-dependant relaxation in
coronary microvessels [111]. EETs have also been implicated in activation of
calcium-dependent potassium channels in vascular smooth muscle, as well
affecting calcium channel activity in cardiac muscle cells [111;114]. 20-HETE
has the opposite effect and inhibits calcium-activated potassium channels [111].
EETs are mediators of vascular tone [115]. 11,12-EET has important antiinflammatory properties in that it prevents leukocyte adhesion to the vascular wall
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[116]. More needs to be learned about cytochrome P450 products and their
potential to possess anti-inflammatory properties.

Cell-Cell Interaction in Eicosanoid Formation:
Cell-cell and cell-tissue interactions are important in producing eicosanoids. This
interaction is lost many times in in vitro homogeneous cell cultures. Cell-cell
interactions are involved in the making of lipoxins. It was initially believed that
more than one cell type may be involved in the production of the lipoxins since it
required two lipoxygenation steps for their synthesis. One example is the
pathway for biosynthesis between the neutrophil and platelet. The neutrophil
houses the 5-LO and the platelet houses the 12-LO, both of which are necessary
to produce lipoxins [108]. Greater than 50% of the LTA4 formed by the neutrophil
is released into the extracellular compartment. Neutrophil-adherent platelets pick
up the LTA4 and convert it, via 12-LOX, to the lipoxins [108]. It is important to
note that the platelet and the neutrophil must be adherent for lipoxin synthesis to
be complete [108]. Another case of lipoxin synthesis that requires tissue-cell
interaction is in the synthesis of the aspirin-triggered lipoxins. When COX 2 is
activated in the presence of aspirin in the endothelium or epithelium by proinflammatory cytokines, it will produce 15(R)-HETE. 15(R)-HETE is released and
then converted to 15-epi-lipoxins by adherent leukocytes [100]. Cells must be
adherent to the initial tissue or cell for complete conversion [100]. Cell-cell
interaction between the PMNs and platelets in the formation of lipoxins is also
important [101].
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Another example of cell-cell interactions in the formation of eicosanoids is
when there is co-incubation of human epidermis and neutrophils. When these
two cell types are incubated together, there is a 90% increase in the cysteinyl
leukotrienes when compared to incubation of neutrophils alone. This indicates
that the epidermis is transforming the LTA4 from neutrophils into cysteinyl
leukotrienes [103]. This is not to say that cysteinyl leukotrienes would not be
formed in a homogeneous culture of neutrophils, but their production would be
dramatically less.

Benefits of EPA and GLA:
There have been many studies demonstrating the anti-inflammatory properties of
dietary EPA and GLA [55;117-119]. As discussed previously, GLA is rapidly
elongated to dihomo-γ-linolenic acid (DGLA), which can be converted to a variety
of anti-inflammatory compounds. DGLA, alone, suppresses leukotriene and
prostaglandin biosynthesis through competition with AA for binding sites on LO
and COX [62]. DGLA is converted to PGE1 via the COX enzymes [57]. PGE1
inhibits platelet aggregation, dilates blood vessels and reduces blood pressure,
and stimulates cyclic AMP formation that inhibits cPLA2 release of proinflammatory AA [57]. PGE1 also inhibits neutrophil chemotaxis and oxygen free
radical release [57]. DGLA can be converted to 15-OH-DGLA, which is an
inhibitor of the 5- and 12-LO enzymes [57]. This reduces the production of proinflammatory compounds such as LTB4. Additionally, neutrophils do not contain
∆-5 desaturase, the enzyme that converts DGLA to AA (Fig. 2.2.1), and,
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therefore, accumulate DGLA rather than AA in cellular phospholipids [120].
Thus, when a neutrophil is stimulated, cPLA2 will release more anti-inflammatory
DGLA than normal.
Dietary EPA has tremendous anti-inflammatory properties. As previously
discussed, eicosanoids derived from EPA are less biologically active than
eicosanoids derived from AA [39]. There are a few key exceptions: lipoxins
derived from EPA are just as potent as lipoxins derived from AA [110].
Furthermore, lipoxins are considered to anti-inflammatory [107]. PGI3 derived
from EPA, is as biologically active as PGI2, derived from AA [77]. PGI2 is thought
of as an anti-inflammatory prostaglandin [78]. Furthermore, EPA inhibits ∆-6
desaturase, a key enzyme in the production of AA from linoleic acid. EPA
competes with AA for incorporation into membrane phospholipids; increasing
EPA in the diet reduces the AA content of phospholipids membranes [60]. EPA
will compete with AA for binding sites on COX and LO. Additionally, EPA is a
better substrate for 12-LO [83]. It is clear that dietary EPA and GLA are important
in the regulation of inflammation and that these fatty acids are capable of
reducing inflammation in both acute and chronic situations. Furthermore, both
EPA and GLA have been shown to induce apoptosis in certain cell types and the
ability to induce apoptosis in neutrophils may lead to a rapid resolution of
inflammation [121-123].
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III. Apoptosis

Apoptosis:
Apoptosis plays a critical regulatory role in the control of the size of cell
populations, normal tissue homeostasis, and resolution of inflammation
[124;125]. Apoptosis is a closely controlled cell process. Out of control
apoptosis can lead to diseases, such as neurodegenerative diseases, and lack of
appropriate apoptosis can contribute to cancer [126]. Cellular control of
apoptosis is very complex and our understanding of this process continues to
grow every day. Yet there is still a lot to be learned on the topic. Cellular
apoptosis can be broken down into two distinct pathways: death receptor
pathway or the mitochondrial pathway [127]. The executioners of apoptosis in
both the death receptor pathway and the mitochondrial pathway are the cysteine
aspartate-specific proteases (caspases) [127]. All caspases have an active site,
containing a cysteine, that cleaves substrates after an aspartic acid residue (AspXxx) [128]. Caspases are initially synthesized as inert zymogens [128]. The
activation of caspases works through a caspase cascade starting with the
initiator caspases.

Death Receptor Pathway of Apoptosis:
In the death receptor pathway, the receptors are from the tumor necrosis factor
(TNF) family (Fig 2.3.1). These receptors include TNF receptor 1, DR3/WSL,
DR6, TRAIL/Apo-2L, and Fas/Apo-1 (CD95) [129]. Once a ligand binds, for
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Figure 2.3.1. Schematic of the death receptor pathway of apoptosis.
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example, Fas ligand to the Fas receptor, a series of cascading events occurs.
First, this interaction causes the formations of an intracellular death-inducing
signaling complex (DISC). This complex forms on the death domain [127]. The
Fas-associated death domain recruits pro-caspase-8, the first of the death
receptor pathway caspase cascade. Pro-caspase-8 is activated through
cleavage via other pro-caspase-8s. This occurs when 2 or more pro-caspase-8s
have aggregated at the Fas-associated death domain through a process known
as induced proximity [127;128]. Caspase-8 is considered an initiator caspase.
Caspase-8 activation can be blocked by the degenerate caspase homologue cFLIP [128]. Caspase-8 activates the executioner caspases, caspase-3, -6, and 7 through cleavage of the pro-caspase forms [127]. The most prevalent caspase
in the cell is caspase-3 [127]. Procaspase-3 (inactive caspase) exists as a 32
kDa protein. Once pro-caspase-3 is cleaved, it becomes active and yields a
heterodimer consisting of p11 and p20 subunits [130]. Interestingly, this
cleavage occurs at an Asp-Xxx site, inferring that caspases have autocatalytic
activation [128]. Caspase-3 is considered the workhorse of apoptosis. Activated
caspase-3 will cleave many proteins, such as cytoskeletal proteins, and proteins
involved in DNA repair, such as polyADP-ribose polymerase (PARP) [130].
Caspase-3, along with caspases-6 and -7, are referred to as the “executioner
caspases” [127].
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Mitochondrial Pathway of Apoptosis:
The mitochondrial pathway of apoptosis is different in initiation than from the
death receptor pathway (Fig 2.3.2). The mitochondrial pathway is usually
initiated via some sort of cellular stress. For example, DNA damage may lead to
apoptosis through the mitochondrial pathway. At this point in time, there are
thought to be more players in mitochondrial apoptosis than there are in the FasFas ligand death receptor pathway. Proteins from the Bcl-2 family primarily
control the mitochondrial pathway. Bcl-2 family members can be broken down
into two groups, pro-apoptotic and anti-apoptotic. A few of the pro-apoptotic
members are; Bax, Bak, Bok, and Bid and a few of the anti-apoptotic members
are; Bcl-2, Bcl-XL, Bcl-W, and Mc1-1 [127;128]. Bcl-2 and Bcl-XL are on the
outer mitochondrial membranes while the pro-apoptotic proteins are cytosolic or
can be present on the membrane [127]. Translocation of the pro-apoptotic Bcl-2
family members to the mitochondrial membrane initiates the apoptotic response.
The pro- and anti-apoptotic Bcl-2 proteins are in a constant tug of war to
determine if the cell is going to live or die. Once enough pro-apoptotic Bcl-2
members have congregated on the mitochondrial membrane, the cell reaches
the point of no return. Most of the pro-apoptotic members in the cytosol are in
the inactive form. They are activated through a variety of mechanisms, including
proteolysis and dephosphorylation [128]. Once enough pro-apoptotic Bcl-2
family members have congregated to over-power the anti-apoptotic Bcl-2 family
members, the mitochondria releases all of its cytochrome c. Cytochrome c is
quickly released from all mitochondria in the cell [127]. Pro-apoptotic Bcl-2s are
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Figure 2.3.2. Schematic of the mitochondrial pathway of apoptosis.
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thought to form large pores in the mitochondria to facilitate the release of the
cytochrome c [128]. Pro-apoptotic Bcl-2 has a structural similarity to the poreforming subunits of dipthera toxin [128]. Other proteins, such as second
mitochondria-derived activator of caspases/direct IAP-binding protein with low pI
(Smac/DIABLO), are also released from the mitochondria at the same time as
cytochrome c [127]. Smac/DIABLO further encourages the completion of
apoptosis by inhibiting inhibitors-of-apoptosis (IAP) proteins [128]. Cytochrome c
combines with apoptotic protease-activating factor-1 (Apaf-1) and pro-caspase-9
to form apoptosomes [127;128]. Unlike other caspases, pro-caspase-9 cannot
be activated by simple cleavage, rather it must be part of the apoptosome [127].
Once caspase-9 is active. it can then cleave pro-caspase-3 and rest of the
pathway is the same as the death receptor pathway. The only other connection
between the two pathways is that caspase-8 can cleave Bid and truncated Bid
translocates to the mitochondria and causes the release of cytochrome c [128].
The majority of the time the two pathways of apoptosis are distinct in the initiation
and only one pathway will proceed [128].

Morphology of Apoptosis:
There are several distinct morphological characteristics of cellular apoptosis.
Kerr et al. [131] first described morphological features via electron microscopy in
1972. Cells shrink and the cytoplasm condenses and the cell will detach from
the surrounding tissue [132]. Microvilli appear and cell density increases as
cytoplasmic organelles compact [133]. The cell continues to degrade through a
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process known as budding when small parts of the cell break off and are
contained within a cellular membrane to form apoptotic bodies [134]. The
chromatin in the nucleus condenses and eventually begins to separate [132].
Condensed pieces of chromatin are often observed within apoptotic bodies [132].
Surrounding tissues and phagocytic cells, such as macrophages and dendritic
cells, typically phagocytose apoptotic bodies [132]. If an apoptotic cell is not
phagocytosed it will continue to degrade via secondary necrosis [134].
Some of the best described biological markers of apoptosis are
internucleosomal DNA fragmentation, caspase activation, cytochrome c release,
and externalization of phosphatidylserine (PS) [126;132]. Internucleosomal DNA
fragmentation is considered a hallmark of late apoptosis. Cellular DNA is
degraded in the internucleosomal regions into double-stranded DNA fragments of
180-200 base pairs by endogenous DNAase, giving a characteristic banding
upon gel electrophoresis [132;134]. Activation of caspases and release of
cytochrome c are both important aspects of the pathways of apoptosis, as
previously discussed. In early apoptosis, PS, which is found on the inner leaflet
of the cell membrane, translocates to the outer leaflet of the cell membrane while
the cell maintains full membrane integrity [135]. In vivo, externalized PS is a
physiological marker that macrophages use to recognize and engulf apoptotic
cells before they degrade via secondary necrosis [41].
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Apoptosis vs. Necrosis:
Degradation via apoptosis is a controlled and ordered process. Apoptosis
typically affects single cells that are scattered throughout a tissue. Conversely,
necrosis affects groups of contiguous cells [133]. Apoptotic cells are unique in
that as they degrade they do not spill their cytoplasmic organelles into the
extracellular environment. Rather, apoptotic bodies are formed that are rapidly
phagocytosed. This rapid clearance of apoptotic bodies allows cell death via
apoptosis to occur without inducing an inflammatory response [136]. In
apoptosis, cells first shrink; in necrosis, cells first swell, causing the plasma
membrane to break and the cell lyses [137]. Necrotic cells degrade rapidly,
losing membrane integrity via lysis. Loss of membrane integrity allows the cell to
spill all its contents, including proteolytic enzymes that cause local tissue damage
and induce an inflammatory response [138]. Necrosis was originally called
oncosis, which is derived from oncos, meaning swelling [137]. Most of the
biochemical markers of apoptosis previously described are absent in a necrotic
cell. It is clear that apoptosis and necrosis are two distinct forms of cellular
death. Apoptosis is considered a normal non-harmful event while necrosis is
indicative of a pathological process [137].

Apoptosis and Polyunsaturated Fatty Acids:
Polyunsaturated fatty acids have been shown to induce apoptosis in a variety of
cell types in vitro. Apoptotic cell death is induced in the pancreatic caner cell
line Mia-Pa-Ca-2 with treatment of a variety of n-3 and n-6 PUFA. Oleic (n-9),
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linoleic (n-6), α-linolenic (n-3), and γ-linolenic (n-6) acids only slightly induced
apoptosis in Mia-Pa-Ca-2 cells [123]. However, the longer chain PUFA,
arachidonic (n-6), cis-parinaric (n-3), eicosapentaenoic (n-3), and
docosahexaenoic (n-3) acids all induced significant amounts of apoptosis
[123;139]. The relative cytoxic potencies of various PUFA are related to the
carbon chain length, the longer the chain the more potent the induction of
apoptosis [123;140]. EPA has also been shown to induce apoptosis in Walker
256 rat carcinoma cells [141]. γ-Linolenic acid has been shown to induce
apoptosis in the human lymphoblast cell lines TK6 and WTK1, chronic myeloid
leukemia (CML), human cervical cancer cell line HeLa, Walker 256 rat carcinoma
cells, and glioma spheroid cell lines U87, U373, and C6 [141-145]. Arachidonic
acid (AA) has been shown to induce apoptosis in the human lymphoblast cell
lines TK6 and WTK1, and chronic myeloid leukemia (CML) [142;143].
Arachidonic acid induced apoptosis has also been demonstrated in human
neutrophils [146]. Lastly, PUFA of the n-3 (EPA) and n-6 (AA) families have
been shown to induce apoptosis in human promyelocytic HL-60 cells [147-149].
The proposed mechanism by which PUFA induce apoptosis in these cell
types is debated and differs for each cell line. Several studies conclude that the
induction of apoptosis in lymphoblast cell lines by AA and GLA is due to cell
arrest in the G-1 phase and by EPA in Mia-Pa-Ca-2 cells via cell cycle arrest
[139;142]. Several studies have also concluded that the induction of apoptosis in
CML by PUFA is independent of AA conversion to eicosanoids or free radical
generation [143]. Conversely, induction of apoptosis in Mia-Pa-Ca-2 by EPA and

56
AA has been shown to be prevented with anti-oxidants implicating free radicals
[123]. The proposed mechanism for the induction of apoptosis by PUFA covers
a broad range and has many disagreements as well as agreements. Thus, the
mechanism by which PUFA induce apoptosis in certain cell lines needs much
work and delineation.

Apoptosis and Lung Inflammation:
Acute respiratory distress syndrome (ARDS) is an acute inflammatory response
characterized by neutrophil accumulation, increased pulmonary capillary
permeability, pulmonary edema, increased pulmonary vascular resistance, and
progressive hypoxemia [4;150]. ARDS is thought to be a neutrophil-mediated
acute inflammatory response. The clearance of neutrophils via apoptosis is
critical in the resolution of acute lung inflammation [124]. Apoptotic neutrophils
are removed from the lung by alveolar macrophages, thereby limiting tissue
damage and reducing inflammation [121;122]. Failure of phagocytosis of
apoptotic neutrophils or neutrophil degradation via necrosis will contribute to and
exacerbate acute lung injury [122]. The polyunsaturated fatty acids, EPA, GLA,
AA, and DHA, are all known to induce apoptosis in certain cell types [123;151].
The ability to modify the eicosanoid profile through enteral nutrition with EPA and
GLA is beneficial in improving clinical outcomes in patients with ARDS [117].
These improvements may be a direct result of a decreased number of
neutrophils in the lung due to increased neutrophil apoptosis and clearance by
macrophages. The ability to increase the number of apoptotic neutrophils in the
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lungs of patients with ARDS may lead to new therapies to enhance resolution of
inflammation and ultimately a more positive outcome.
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Part 3
Experimental Investigation of the Effects of n-3 and n-6 Polyunsaturated
Fatty Acids on Human Promyelocytic HL-60 Cells

82
I. Eicosapentaenoic Acid and γ-Linolenic Acid Induce Apoptosis in HL-60
Cells1

1
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Abstract:
Enteral nutrition with eicosapentaenoic acid (EPA; 20:5 n-3) and γ-linolenic acid
(GLA; 18:3 n-6) decreased pulmonary inflammation by reducing neutrophil
counts and chemotactic factors in bronchoalveolar lavage fluid during acute
respiratory distress syndrome (ARDS). We hypothesized that the antiinflammatory effects of EPA and GLA may be due, in part, to induction of
neutrophil apoptosis. The purpose of this study was to determine if EPA and
GLA, alone or in combination, trigger apoptotic cell death in human promyelocytic
leukemia HL-60 cell line. HL-60 cells were incubated with 10, 20, 50, and 100 µM
EPA, GLA or various combinations of EPA and GLA for 2, 4, 8, 12 and 24 hours.
Oleic acid (18:1 n-9) was used as a fatty acid control. Flow cytometry using dualstaining with propidium iodide and annexin V-FITC assessed apoptosis, necrosis
and viability. Apoptosis was verified by DNA fragmentation as assessed by
agarose gel electrophoresis. EPA, GLA, and various combinations of EPA and
GLA significantly induced apoptosis and reduced cell viability in HL-60 cells.
Viability was significantly reduced to the same extent with the combination of 50
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µM EPA\20 µM GLA as compared with 100 µM EPA. These data indicate that
EPA and GLA, alone or in combination, reduce cell survival by induction of
apoptosis. Thus, induction of apoptosis by select dietary n-3 (EPA) and n-6
(GLA) polyunsaturated fatty acids may be the mechanism of the resolution of
pulmonary inflammation in ARDS.

Key Words: Fish oil, Borage Oil, Cell Culture, Polyunsaturated Fatty Acids,
ARDS, Inflammation, Pulmonary, Sepsis, Neutrophil, Necrosis

Introduction:
Polyunsaturated fatty acids (PUFA) from fish and borage oil have beneficial
dietary effects in variety of health problems such as cardiovascular disease,
inflammation, acute respiratory distress syndrome (ARDS) and sepsis [1-3].
Apoptosis has been shown to be induced after exposure to individual PUFA
including Eicosapentaenoic acid (EPA; 20:5 n-3), γ-linolenic acid (GLA; 18:4 n-6)
and arachidonic acid (AA; 20:4 n-6) in a variety of cell types, in vitro [3], however,
the combined effects of EPA and GLA on apoptosis is not known.
Eicosapentaenoic acid is found in fish oils and GLA in borage, evening
primrose and blackcurrant seed oils [4-6]. We previously showed that enteral
nutrition with specialized diets containing EPA and GLA reduced the number of
neutrophils in the bronchoalveolar lavage fluid, reduced pulmonary inflammation,
and improved clinical outcomes of patients with ARDS [7]. These improvements
may be a direct result of fewer neutrophils in the lung due to their reduced
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migration and/or increased clearance by alveolar macrophages. Phagocytosis of
apoptotic neutrophils by macrophages is an important physiological process in
the resolution of pulmonary inflammation [8]. Eicosapentaenoic acid from dietary
fish oil is incorporated into and reduces the content of AA in cell membrane
phospholipids. Eicosapentaenoic acid is available for enzymatic conversion to 3series prostaglandins and 5-series leukotrienes [9]. These eicosanoids have
anti-inflammatory properties and are considered to be less biologically active
than the 2-series prostaglandins and 4-series leukotrienes from AA [10]. γLinolenic acid is an n-6 fatty acid and is elongated to dihomo-γ-linolenic acid
(DGLA) which can be converted to prostaglandin E1 or a 15-lipoxygenase
metabolite, 15-hydroxyeicosatrienoic acid (15-HETriE), which has been shown to
attenuate leukotriene B4 (LTB4) formation by inhibiting 5-lipoxygenase [11].
Prostaglandin E1 has also been shown to indirectly decrease leukotriene
formation by the inhibition of 5-lipoxygenase [12]. The activation of neutrophils
[4] with lipopolysaccharide will prolong their survival, in vitro [13]. This effect can
be blocked with LTB4 receptor antagonists, implying that LTB4 plays a critical role
in neutrophil viability.
We hypothesize that the anti-inflammatory effects of EPA and GLA may
be due, in part, to induction of neutrophil apoptosis. The purpose of this study
was to determine if EPA and GLA, alone or in combination, trigger apoptotic cell
death in the human promyelocytic leukemia HL-60 cell line. We used various
physiological concentrations of these fatty acids and at ratios similar to those
used in our previous dietary studies, as this may help us understand the

85
beneficial effects of dietary fish and borage oil in the attenuation of pulmonary
inflammation in acute lung injury. We used the HL-60 cell line because it is the
preferred immortalized cell line for the study of human neutrophil responses, in
vitro [14;15].

Materials and Methods:
Cells. The human promyelocytic leukemia cell line HL-60 was obtained from Dr.
Robert Hall (Univ. of Tennessee Medical Center, Knoxville, TN). Cells were
cultured in RPMI 1640 medium with phenol red supplemented with HEPES (25
mM; BioWhittacker, Walkersville, MD), 10 % heat inactivated fetal bovine serum,
1 % penicillin-streptomycin solution (Sigma Chemical, St. Louis, MO), and 1 % Lglutamine (BioWhittaker, Walkersville, MD). Cells were maintained at 37°C in an
atmosphere of 5 % CO2 and 95 % room air in a NAPCO model 5410 incubator
(Precession Scientific, Chicago, IL).

Treatments.

All chemicals and reagents were from Sigma Chemical (St. Louis,

MO), unless otherwise noted. Cell number and viability were assessed using a
hemacytometer and trypan blue dye exclusion. Cells were plated in sterile
Costar 6 well cell culture plates (Corning, Corning, NY) at a concentration of
300,000 cells/mL. Cells were treated with EPA (100, 50, 20, and 10 µM), GLA
(100, 50, 20, and 10 µM), and all possible combinations of the 50, 20, and 10 µM
EPA and GLA. All fatty acid treatments were conducted under yellow
incandescent light. Methanol was used as vehicle control and oleic acid was
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used as fatty acid control. All treatments were conducted in triplicate at 2, 4, 8,
12, and 24-hour time points.

Detection of apoptosis (flow cytometry). Detection of apoptosis by flow cytometry
was performed using Annexin V-FITC apoptosis detection kit (BD Pharmingen,
San Diego, CA). Once a desired time point was reached, cells were removed
from six well plates and washed with phosphate buffered saline containing 0.1 %
bovine serum albumin. Cells were pelleted using an Eppendorf centrifuge, model
5415D (Brinkmann Instuments, Westbury, NY) at 1100 x g (3400 rpm) for 2
minutes. Cells were resuspended in 100 µl of 1X annexin V binding buffer (kit).
Annexin V-FITC (5 µl) and propidium iodide (10 µl) were added to each treatment
in the dark (both from kit). Cells were incubated at room temperature for 15
minutes and kept in the dark. Cell suspensions were raised to a final volume of
500 µl with 1X annexin V binding buffer and placed in 10x75 Falcon culture tubes
(Becton Dickinson, Franklin Lakes, NJ) on ice and kept in the dark until flow
cytometric analysis. Hydrogen peroxide (10 µM) treated cells were used as a
positive control for flow cytometry to properly set the scatter plot gates (i.e.
hydrogen peroxide treated cells stained with only annexin V-FITC and hydrogen
peroxide treated cells stained with only PI). Flow cytometry was performed using
a Becton-Dickenson FACScan flow cytometer and Cell Quest software version
1.2 (Becton-Dickenson, San Jose, CA).
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Detection of apoptosis (DNA laddering). Detection of apoptotic DNA laddering
was performed as described by McGahon et al., 1995 [16]. Cells at a
concentration of 225,000 cell/ml were pelleted using an Eppendorf centrifuge,
model 5415D (Brinkmann Instruments, Westbury, NY) at 1100 x g (3400 rpm) for
2 minutes. Cells are resuspended in 20 µl lysis buffer (20 mM EDTA
(Mallinckrodt, St. Louis, MO), 100 mM Tris, pH 8.0, 0.8 % (w/v) sodium lauryl
sarcosine (Bioworld, Dublin, OH)). RNase/T1 cocktail mix (10 µl 1 mg/ml,
Ambion, Austin, TX) was added and mixed well by flicking the tip of the tube.
This was incubated at 37°C for 75 minutes. Proteinase K (10 µl, Ambion, Austin,
TX) was added and incubated for 120 minutes at 50°C. Loading buffer (5 µl) was
added to samples and samples were loaded onto a 1.5% agarose gel. Gel was
run for 200 minutes at 35 volts in 1X TAE buffer using Bio-Rad mini subcell GT
(Bio-Rad, Hercules, CA) and a Pharmacia EPA 250/200 power supply
(Pharmacia, Peapack, NJ). Molecular weight marker XIV was used (Roche,
Mannheim, Germany). Camptothecin (CAM) at a concentration of 5 µM was
used as a positive control for apoptosis. Bands of DNA were visualized using
ethidium bromide (Promega, Madison, WI) on a FlourChem 8000 imager (Alpha
Innotech, San Leandro, CA).

Statistics. Data are expressed as mean percent ± SEM. Differences in mean
percent were determined by a Kruskal-Wallace non-parametric rank test with
pairwise group comparisons to determine where the differences lay. Data were
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analyzed using CRUNCH version 4.0 statistical package (Crunch Software Corp.,
Oakland, CA).

Results:
Flow Cytometry: The effects of media, methanol (vehicle) and oleic acid on
viability, apoptosis, and necrosis was determined by flow cytometry after a 24hour incubation in HL-60 cells (Table 3.1.1). The monounsaturated fatty acid,
oleic acid, vehicle control (methanol), or cell media alone did not induce
apoptosis or necrosis and did not affect viability after 24 hours in HL-60 cells.
Oleic acid (100 µM) also did not affect apoptosis, necrosis or viability at 2, 4, and
8 hours (data not shown). Figure 3.1.1 shows that there was no difference on
apoptosis, necrosis and viability over wide range of oleic acid concentrations (10100 µM) when compared with 0 µM oleic acid in HL-60 cells. Since there were
no time or concentration dependent effects of oleic acid on apoptosis, necrosis
and viability in HL-60 cells, the control data reported in the rest of the study was
the average of the 2, 4, 8, 12, and 24-hour incubations over all oleic acid
concentrations (n = 120). The average basal rate was, as a proportion of the
total cell population, 92.3 % viability, 4.8 % apoptosis, and 2.7 % necrosis.
Flow cytometry scatter plots of 100 µM oleic acid, 50 µM EPA, 100 µM
GLA and the combination of 50 µM EPA and 20 µM GLA are shown in figure
3.1.2.
The effects of various concentrations of EPA on apoptosis, necrosis and
viability in HL-60 cells are shown in Figure 3.1.3. Eicosapentaenoic acid at a
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Table 3.1.1. Effects of controls on apoptosis, viability, and necrosis on HL-60
cells after 24-hour incubation.1
24 Hour Incubation
% Apoptosis
% Viability
% Necrosis
a
a
a
4.74
90.45
2.52
Oleic Acid (100 µM)
±0.24
±0.63
±0.82
Methanol
3.88a
93.95a
1.90a
±1.57
±1.90
±0.76
a
a
a
No Treatment
3.31
93.73
2.64
±0.77
±0.50
±0.28
a

Means within a column not sharing like superscripts are different (P<0.05).
Mean percent of cell population ± SEM as measured using flow cytometry with propidium iodide and
annexin V-FITC staining.
1
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Figure 3.1.1. Effects of oleic acid on viability, apoptosis, and necrosis of HL-60
cells after 12-hour incubation.1
a,b

For a given variable, values that do not share the same superscript letter are different (P <
0.05).
1
Mean ± SEM of the % viability, apoptosis, and necrosis as measured using flow cytometry with
propidium iodide and annexin V-FITC staining.

100 µM Oleic Acid
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50 µM EPA

50 µM EPA 20 µM GLA

Figure 3.1.2. Flow cytometry scatter plots of 100 µM oleic acid, 50 µM
EPA, 100 µM GLA and the combination of 50 µM EPA and 20 µM GLA.
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Figure 3.1.3. Effects of eicosapentaenoic acid on viability, apoptosis, and
necrosis of HL-60 cells after 12-hour incubation.1
a,b,c,d

For a given variable, values that do not share the same superscript letter are different (P <
0.05).
1
Mean ± SEM of the % of control for viability, apoptosis, and necrosis as measured using flow
cytometry with propidium iodide and annexin V-FITC staining.
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concentration of 50 µM induced a significant increase in apoptosis after a 12hour incubation in HL-60 cells. Viability, apoptosis and necrosis were significantly
different from control at 10 µM, 20 µM, 50 µM, and 100 µM EPA.
Eicosapentaenoic acid at 100 µM did not cause an additional increase in
apoptosis as compared with 50 µM EPA. Secondary necrosis, a feature of endstage apoptosis, was significantly increased with 50 µM and 100 µM EPA as
compared with the lower concentrations of EPA. Secondary necrosis was
greatest with 100 µM EPA. These effects of EPA (10-100 µM) on apoptosis and
secondary necrosis resulted in a significant corresponding reduction in cell
viability. We also noted that duration of the incubation with EPA across all
concentrations affected apoptosis, necrosis, and cell viability (data not shown).
For example, EPA (100 µM) reduced viability to 27.6% of control, however, this
was due to a substantial increase (2211.4%) in secondary necrosis at 24 hours.
EPA (10-100 µM) at 2 and 4 hours did not affect apoptosis, necrosis and viability
as compared with control.
The effects of various concentrations of GLA on apoptosis, necrosis and
viability in HL-60 cells are shown in Figure 3.1.4. GLA exhibits both time and
concentration dependent effects on apoptosis, necrosis, and viability in HL-60
cells. There was a significant decrease in viability and increase in secondary
necrosis with 100 µM GLA as compared with control and 20 µM GLA. Apoptosis
was not induced over the entire range of GLA concentrations as compared with
control at 12 hours. We also found that with a 24-hour incubation, viability was
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Figure 3.1.4. Effects of gamma-linolenic acid on viability, apoptosis, and
necrosis of HL-60 cells after 12-hour incubation.1
a,b,c

For a given variable, values that do not share the same superscript letter are different (P <
0.05).
1
Mean ± SEM of the % of control for viability, apoptosis, and necrosis as measured using flow
cytometry with propidium iodide and annexin V-FITC staining.
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significantly decreased and secondary necrosis increased with 50 µM and 100
µM GLA as compared with control, 10 and 20 µM GLA (data not shown). γLinolenic acid (0-100 µM) had no effect on viability, apoptosis, and secondary
necrosis at the 2, 4, and 8-hour incubation times.
The combined effects of various concentrations of EPA and GLA on
apoptosis, necrosis and viability in HL-60 cells are shown in Figure 3.1.5.
Apoptosis, necrosis and viability were not significantly different between control
and 10 µM EPA combined with either 10, 20, 50 µM GLA or 20 µM EPA
combined with either 10, 20, 50 (Figure 3.1.5A). However, 50 µM EPA and 20
µM GLA significantly reduced viability, increased apoptosis and secondary
necrosis (Figure 3.1.5B). The combined effects 50 µM EPA and 50 µM GLA and
50 µM EPA and 20 µM GLA significantly reduced viability, increased apoptosis
and secondary necrosis. Viability was significantly reduced to the same extent
with the combination of 50 µM EPA\20 µM GLA (Figure 3.1.5B) as compared
with 100 µM EPA (Figure 3.1.3A).

DNA Laddering. The effect of EPA on DNA fragmentation of HL-60 cells at 12
hour incubation is shown in Figure 3.1.6. There was visible DNA banding of
multimers of 180-200 base pairs with 50 and 100 µM EPA at 12 hours. Gammalinolenic acid, regardless of concentration, did not cause visible DNA banding
(data not shown). The effect of various combinations of EPA and GLA on DNA
fragmentation of HL-60 cells at the 12-hour incubation is shown in Figure 3.1.7.
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Figure 3.1.5. Effects of various combination of 0, 10, or 20 µM EPA (panel A)
and 50 µM EPA (panel B) in the presence or absence of 0, 10, 20, or 50 µM GLA
on viability, apoptosis, and necrosis of HL-60 cells after 8-hour incubation.1
*

For a given variable, value is different from control (P < 0.05).
Mean ± SEM of the % of control for apoptosis, viability, and necrosis as measured using flow
cytometry with propidium iodide and annexin V-FITC staining.
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Figure 3.1.6. Effects of eicosapentaenoic acid on whole DNA fragmentation of
HL-60 cells after 12-hour incubation.
Lanes: M= marker lane containing a 100 bp ladder of DNA fragments from 2642 bp, 1500-100 bp;
1 = negative control; 2 = Positive control (5 µM CAM); 3 = 100 µM EPA; 4 = 50 µM EPA; 5 = 20
µM EPA; 6 = 10 µM EPA.
Gel: 1.5 % agarose gel.
Running conditions: 200 minutes at 35 volts in 1X TAE buffer.
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Figure 3.1.7. The effects of various concentrations of EPA and GLA on whole
DNA fragmentation of HL-60 cells after 12-hour incubation.
Lanes: M= marker lane containing a 100 bp ladder of DNA fragments from 2642 bp, 1500-100 bp;
1 = negative control; 2 = Positive control (5 µM CAM); 3 = 50 µM EPA\50 µM GLA; 4 = 50 µM
EPA\20 µM GLA; 5 = 50 µM EPA\10 µM GLA; 6 = 20 µM EPA\50 µM GLA; 7 = 20 µM EPA\20 µM
GLA.
Gel: 1.5 % agarose gel.
Running conditions: 200 minutes at 35 volts in 1X TAE buffer.
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The combined effects of 50 µM EPA\50 µM GLA, 50 µM EPA\20 µM GLA, and 50
µM EPA\10 µM GLA produced visible DNA banding of multimers of 180-200
base pairs.

Discussion:
This study shows that eicosapentaenoic acid (EPA) alone or in combination with
γ-linolenic acid (GLA) induced apoptosis and secondary necrosis in human
promyelocytic HL-60 cells. These results are not likely due to non-specific
effects of fatty acids as oleic acid had no effect on apoptosis and secondary
necrosis in HL-60 cells (Table 3.1.1). Oleic acid is considered an appropriate
fatty acid control as shown in many dietary polyunsaturated fatty acid studies
[17;18]. The HL-60 cell line is considered to be the preferred immortalized cell
line for the to study human neutrophil responses in vitro [14;15].
Eicosapentaenoic acid and GLA are dietary long chain polyunsaturated fatty
acids from the n-3 and n-6 series, respectively, and when used in combination in
specialized diets have been shown to have anti-inflammatory actions, in vivo
[7;10]. We also show that various molar ratios of the combination of EPA and
GLA had similar effects on reducing cell viability as compared with EPA alone.
For example, a total fatty acid load of 70 µM, 50 µM EPA and 20 µM GLA,
reduced cell viability as effectively as 100 µM EPA alone. Thus, EPA, GLA, and
the combination of EPA and GLA have specific biological activity with respect to
a reduction in cell viability in HL-60 cells. Dietary PUFA may have important
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therapeutic applications in the clinical management of patients with inflammatory
disorders by their ability to modulate cell viability by inducing apoptosis.
HL-60 cells share many functional characteristics with peripheral blood
neutrophils, such as containing azurophilic granules, and are, therefore,
considered the preferred immortalized cell line model for studying human
neutrophil responses in vitro [14;15]. Human neutrophils are short lived and will
undergo apoptosis in 6-12 hours in vitro. HL-60 cells are an immortal cell line
and do not spontaneously undergo apoptosis at an accelerated rate. Thus, HL60 cells are a good substitute to measure the induction of apoptosis by fatty
acids and are a good model for peripheral blood neutrophils [15]. Several
limitation to the HL-60 cells as a model for neutrophils are that HL-60 cells are a
cancer cell line and therefore have different cell cycle regulation than do human
neutrophils. Furthermore, HL-60 cells and neutrophils do express the identical
gene products. For example, HL-60 cells express Bcl-2 while human neutrophils
do not express this protein. Besides the few differences, the HL-60 cell line is
still considered the preferred cell line to model human neutrophils.
Apoptosis plays a critical regulatory role in the control of the size of cell
populations, normal tissue homeostasis, and resolution of inflammation [8;19].
We performed flow cytometry after dual-staining with Annexin V as a FITC
conjugate in combination with propidium iodide (PI) to differentiate between
viable, apoptotic and secondary necrotic HL-60 cells. One of the earliest events
in apoptosis is the redistribution of phosphatidylserine (PS) from the inner to the
outer leaflet of the cell membrane. During the early phase of apoptosis, the cell
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has full membrane integrity [20;21] and Annexin V-FITC is unable to enter the
cell and binds only to externalized PS. Since propidium iodide (PI) is too large to
pass through the intact cell membrane, it binds to cellular DNA if there is a
disruption of cell membrane integrity. Therefore, viable cells will contain neither
stain, apoptotic cells stain with Annexin V-FITC and secondary necrotic cells will
contain both stains. In vitro, secondary necrotic cells have been defined to be in
the phase following apoptosis [22;23]. Thus, cells with both stains were most
likely due to apoptosis leading to secondary necrosis.
Apoptosis in HL-60 cells followed a dose dependent response to EPA.
Substantial loss of cell viability was evident with the higher concentrations of
EPA, GLA, and the combination of EPA and GLA at the 12- and 24-hour
incubations. Thus, the large decrease in cell viability, particularly at 24-hours, is
attributed to apoptosis leading to secondary necrosis. In vivo, secondary
necrosis occurs when there is a deficiency in the downstream phagocytosis
clearance mechanism [8]. If apoptotic cells or apoptotic bodies are not
phagocytosed they continue to degrade via secondary necrosis [24]. The
translocation of PS to the outer leaflet of the membrane is the means by which
phagocytic macrophages recognize apoptotic cells for phagocytosis in vivo [25].
Since HL-60 cells are cultured in vitro with no phagocytic macrophages in the
culture media, they degenerate via secondary necrosis.
It has been reported that HL-60 cells treated with 120 µM EPA reduced
cell viability to 44 % of control and apoptosis increased 438 % of control at 24
hours [26]. In the present study, 100 µM EPA at 24 hours reduced viability to 27
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% of control and increased apoptosis to 263 % of control. This difference in the
extent of apoptosis is most likely due to the fact that the former study used a
greater concentration of EPA than the present study. They also reported no
detectable DNA fragmentation in HL-60 cells that were treated with EPA using
DNA-PI flow cytometry and terminal deoxynucleotidyltransferase dUTP nick end
labeling (TUNEL) flow cytometry [26]. However, we were able to detect visible
apoptotic DNA fragmentation using gel electrophoresis at 12 hours with 50 and
100 µM EPA treated HL-60 cells.
One of the later stages of apoptosis is DNA fragmentation [24]. The DNA,
fragmented between nucleosomes by activated endonucleases, which upon
agarose gel electrophoresis give rise to a characteristic DNA ladder pattern of
180-200 base pair multimers [27]. We used camptothecin (CAM) as a positive
control for DNA fragmentation because it is a potent inhibitor of topoisomerase I
and induces DNA fragmentation in a dose dependent manner [28]. Other studies
have reported visible DNA fragmentation of HL-60 cells with 100 µM EPA at 12-,
24-, and 30-hour incubations [3]. We demonstrated positive DNA fragmentation
with 50 and 100 µM EPA after 12-hour incubation in HL-60 cells. Although DNA
fragmentation using gel electrophoresis was not visible for the GLA treated HL60 cells, apoptosis was detected by flow cytometry. This may be due to a small
percent increase in apoptosis which apparently was not sufficient to be detected
by agarose gel electrophoresis.
Acute respiratory distress syndrome (ARDS) is an acute inflammatory
process characterized by neutrophil accumulation, increased pulmonary capillary
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permeability, pulmonary edema, increased pulmonary vascular resistance, and
progressive hypoxemia [29;30]. Enteral nutrition with a diet containing EPA and
GLA reduced pulmonary inflammation and improved gas exchange and clinical
outcomes in patients with the ARDS [7]. Eicosapentaenoic acid and GLA have
been shown to improve lung microvascular permeability, oxygenation,
cardiopulmonary function and reduce pro-inflammatory eicosanoid synthesis in
animal models of acute lung injury and in human ARDS [7;10]. Additionally there
was a substantial reduction in the total number of inflammatory cells and
neutrophils in bronchoalveolar lavage fluid [7].
The combination of fish and borage oils are also effective in suppressing
synthesis of the pro-inflammatory 2-series prostaglandins and 4-series
leukotrienes by alveolar macrophages in endotoxin-induced lung injury.
Recently, Barham et al., 2000 [31] showed that dietary EPA and GLA
supplementation for three weeks in humans reduced the synthesis of
leukotrienes and did not increase the release of arachidonic acid by neutrophils
after stimulation with ionophore A23187. They showed that GLA
supplementation alone for three weeks increased serum arachidonic acid levels
in serum. In contrast, the combination of EPA and GLA did not increase
arachidonic acid in serum after three weeks. Thus, the appropriate combination
of dietary oils for dietary supplementation may avoid potentially adverse side
effects of supplementation with a single dietary oil.
Leukotriene B4 plays a critical role in neutrophil viability and chemotaxis.
Our previous dietary effects may be due to diminished LTB4-derived chemotactic
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activity in bronchoalveolar lavage fluid, and/or a reduction in inflammatory cell
survival due to an increase in neutrophil apoptosis. Previous studies have
demonstrated that neutrophils activated with lipopolysaccharide, in vitro, prolongs
neutrophil survival [13]. This prolonged survival can be blocked with LTB4
receptor antagonists. A reduction of neutrophils in the lung would be beneficial
by limiting local tissue injury [32]. Since the elimination of neutrophils is
physiologically regulated by apoptosis, the potential to induce apoptosis by
dietary lipids would lead to enhanced resolution of inflammation. Thus, induction
of neutrophil apoptosis by select dietary PUFA, EPA and GLA, may contribute to
improvements in clinical outcomes in ARDS [7].
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II. Role of Downstream Metabolic Processing of Pro-inflammatory Fatty
Acids by 5-Lipoxygenase in HL-60 Cell Apoptosis1
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Abstract:
Pro-inflammatory eicosanoids formed from arachidonic acid (AA) by
lipoxygenase (LO) and cyclooxygenase (COX) pathways have been shown to
inhibit apoptosis in certain cell types. This study determined if inhibition of LO
and COX increased apoptosis in AA treated HL-60 cells, in vitro. HL-60 cells
were incubated with 50 µM AA and an enzyme inhibitor (1-10 µM) for either
COX, LO, 12-LO, and 5-LO for 12 hours. Flow cytometry was used to assess
viability, apoptosis, and necrosis. Apoptosis was further assessed using TUNEL
and DNA fragmentation. The highest concentration of LO inhibitors, but not COX
inhibitors, decreased viability and increased apoptosis and necrosis in the
presence of exogenous AA. These results suggest that disruption of the
metabolism of AA by LO, in particular 5-LO, decreases cell survival and
increases apoptosis. Thus, downstream metabolic processing of AA by LO but
not COX plays a critical role in the regulation of HL-60 cell apoptosis.

Key Words: Polyunsaturated Fatty Acids, ARDS, Inflammation, Pulmonary,
Neutrophil, Necrosis

112
Introduction:
Arachidonic acid (AA, 20:4 n-6) is a polyunsaturated fatty acid (PUFA) and a
precursor of the pro-inflammatory 2-series prostaglandins and 4-series
leukotrienes. The lipoxygenase and cyclooxygenase enzymes convert AA to the
4-series leukotrienes, 2-series prostaglandins, and other bioactive products [1].
Excessive release of AA-derived metabolites from inflammatory cells, including
neutrophils and macrophages have been implicated in the development of septic
shock, systemic inflammatory response syndrome (SIRS), acute lung injury, and
the acute respiratory distress syndrome (ARDS) [2]. The measurement of
elevated levels of AA metabolites, including leukotriene B4 (LTB4), prostaglandin
E2, and thromboxane B2, in bronchoalveolar lavage (BAL) fluid in patients with
ARDS and/or SIRS has supported their role in the pathophysiology of pulmonary
inflammation and ARDS [3;4].
Leukotriene B4, a product of 5-lipoxygenase (5-LO), is released from
activated alveolar macrophages and plays a major role in adherence,
chemotaxis, and granulation of polymorphonuclear (PMN) leukocytes, as well as
enhancing the ability of PMNs to secrete oxygen free radicals and proteolytic
enzymes [5;6]. Previous animal and clinical studies has shown that enteral
nutrition supplementation with eicosapentaenoic acid (EPA, 20:5n-3) and γlinolenic acid (GLA, 18:3 n-6) from fish and borage oil, respectively, reduces
pulmonary inflammation as assessed by a reduction in number of neutrophils and
levels of LTB4 in BAL fluid in acute lung injury and ARDS [7]. However, it is not
known if the resolution of pulmonary inflammation in those studies was due to a
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decrease in neutrophil chemotaxis and/or an increase in apoptosis. The
downstream metabolic processing of AA may be critical for prolonged
inflammatory cell survival since neutrophil apoptosis is accelerated in the
absence of 5-LO products of arachidonic acid [8;9].
It is been shown that diets supplemented with dietary fish and borage oil
reduce AA and increase EPA concentrations in tissue and inflammatory cell
phospholipids [10;11]. Increased concentrations of EPA in cellular phospholipids
can compete with AA for lipoxygenase (LO) and cyclooxygenase (COX), which
will reduce pro-inflammatory eicosanoid formation from AA [11;12]. We
previously showed that EPA and GLA, and various combinations of EPA and
GLA significantly induced apoptosis and reduced cell viability in a time and
concentration dependant manner in human promyelocytic HL-60 cells, in vitro
[13]. A number of studies have shown that AA metabolism is linked to cell
proliferation and survival during inflammation and cancer [8;14;15]. The purpose
of this study was to determine if the addition of various LO and COX enzyme
inhibitors of AA metabolism would affect cellular viability, apoptosis, and necrosis
of AA-treated HL-60 cells.

Materials and Methods:
Cells. The human promyelocytic leukemia cell line HL-60 was obtained from
American Type Tissue Culture Collection (Manassas, VA). We used the human
promylocytic HL-60 cell line because it is considered to the preferred
immortalized cell line for the study of human neutrophils responses in vitro [16].
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Cells were cultured in RPMI 1640 medium with phenol red supplemented with
HEPES (25 mM; BioWhittacker, Walkersville, MD), 10 % heat inactivated fetal
bovine serum, 1 % penicillin-streptomycin solution (Sigma Chemical, St. Louis,
MO), and 1 % L-glutamine (BioWhittacker, Walkersville, MD). Cells were
maintained at 37°C in an atmosphere of 5 % CO2 and 95 % room air in a NAPCO
model 5410 incubator (Precision Scientific, Chicago, IL).

Treatments.

All chemicals and reagents were from Sigma Chemical (St. Louis,

MO) unless otherwise noted. Cell number and viability were assessed using a
hemacytometer and trypan blue dye exclusion technique. Cells were plated in
sterile Costar 6 well cell culture plates (Corning, Corning, NY) at a concentration
of 300,000 cells/ml. Cells were treated with 50 µM AA in the presence of an
enzyme inhibitor for 12 hours. Compounds used to inhibit enzymes were from
Biomol (Plymouth Meeting, PA). Each fatty acid was treated with inhibitors for
COX 1 & 2 (ibuprofen [(±)-2-(4-isobutylphenyl) propionic acid]; 1, 5, and 10 µM),
5, 12, 15-LO (NDGA [nodihydroguaiaretic acid]; 1, 5, and 10 µM), 12-LO
(baicalein [5,6,7-trihydroxyflavone]; 1, 5, and 10 µM), 5-lipoxygenase (AA-861 [2(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone]; 1, 5, and 10
µM), and 5-lipoxygenase activating protein (MK-886; 1, 5, and 10 µM). All fatty
acid treatments were conducted under yellow incandescent light. Methanol and
DMSO were used as vehicle controls and oleic acid was used as fatty acid
control. All treatments were incubated in quadruplicate.
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Detection of apoptosis (flow cytometry). Detection of apoptosis by flow cytometry
using Annexin V-FITC and propidium iodide stains (BD Pharmingen, San Diego,
CA) was performed as previously described by Gillis et al., 2002 [13]. After 12hour incubation cells were washed once with phosphate buffered saline
containing 0.1 % bovine serum albumin. Cells were pelleted using an Eppendorf
centrifuge, model 5415D (Brinkmann Instuments, Westbury, NY) at 1100 x g
(3400 rpm) for 4 minutes. Cells were resuspended in 100 µl of 1X annexin V
binding buffer (BD Pharmingen, San Diego, CA). Annexin V-FITC (5 µl) and
propidium iodide (10 µl) were added to each treatment in the dark. Cells were
incubated at room temperature for 15 minutes and kept in the dark. Cell
suspensions were raised to a final volume of 500 µl with 1X annexin V binding
buffer and placed in 10x75 Falcon culture tubes (Becton Dickinson, Franklin
Lakes, NJ) on ice and kept in the dark until flow cytometric analysis. Flow
cytometry was performed using a Becton-Dickenson FACScan flow cytometer
and Cell Quest software version 1.2 (Becton-Dickenson, San Jose, CA).

Detection of apoptosis (DNA laddering). Detection of apoptotic DNA laddering
was performed as described by McGahon et al., 1995 [17]. Cells at a
concentration of 225,000 cell/ml were pelleted using an Eppendorf centrifuge,
model 5415D (Brinkmann Instruments, Westbury, NY) at 1100 x g (3400 rpm) for
2 minutes. Cells were resuspended in 20 µl lysis buffer (20 mM EDTA
(Mallinckrodt, St. Louis, MO), 100 mM Tris, pH 8.0, 0.8 % (w/v) sodium lauryl
sarcosine (Bioworld, Dublin, OH)). RNase/T1 cocktail mix (10 µl 1 mg/ml,
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Ambion, Austin, TX) was added and mixed well by flicking the tip of the tube.
This was incubated at 37°C for 75 minutes. Proteinase K (10 µl, Ambion, Austin,
TX) was added and incubated for 120 minutes at 50°C. Loading buffer (5 µl) was
added to samples and samples were loaded onto a 1.5% agarose gel. Gel was
run for 200 minutes at 35 volts in 1X TAE buffer using Bio-Rad mini subcell GT
(Bio-Rad, Hercules, CA) and a Pharmacia EPA 250/200 power supply
(Pharmacia, Peapack, NJ). Molecular weight marker XIV was used (Roche,
Mannheim, Germany). Bands of DNA were visualized using ethidium bromide
(Promega, Madison, WI) on a FluorChem 8000 imager (Alpha Innotech, San
Leandro, CA).

Detection of apoptosis (TUNEL). Detection of apoptosis by TUNEL assay was
performed using the in situ death detection, POD kit (Roche, Mannheim,
Germany). Approximately 20,000 cells were cytospun at 500 rpm for 5 minutes
(Cytospin3, Shandon, England). Cells were air dried and fixed with Carson
solution. Slides were rinsed twice with PBS and were incubated in
cytofix/cytoperm solution (100 µl) at 4°C for 20 minutes (Pharmagen, San Diego).
Slides were rinsed in perm/wash buffer. Slides were blocked for 10 minutes (100
µl of 0.3% H2O2 in methanol) and rinsed in PBS and allowed to dry. 50 µl of
TUNEL reaction mixture (kit) was added to slides and incubated in a humidified
chamber for 60 minutes at 37°C. Hoechst stain (100 µl) was added and the slides
were incubated for 30 minutes at 37°C. Slides were rinsed with PBS and
protected with cover slips. Slides were analyzed under an Olympus BX51
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fluorescent microscope (Olympus Optical Co., LTD., Japan) and images were
captured with a Magmafire SP CCD camera (Optronics, Goleta, CA).

Statistics. Data are expressed as mean percent ± SE. Differences in mean
percent were determined by one-way analysis of variance followed by REGWF
mean separation to determine statistical significance. P < 0.05 was considered
significant. Data were analyzed using CRUNCH version 4.0 statistical package
(Crunch Software Corp., Oakland, CA).

Results:
Oleic acid, methanol (solvent for fatty acids and inhibitors), and DMSO (solvent
for baicalein; data not shown) did not induce necrosis or apoptosis and did not
affect HL-60 cell viability after 12-hour incubation [13]. Arachidonic acid can be
metabolized by a variety of pathways that can be blocked with enzyme inhibitors
(Figure 3.2.1.).
The effects of ibuprofen (cyclooxygenase 1 and 2 inhibitor) on viability,
apoptosis, and necrosis in AA (50 µM) treated HL-60 cells are shown in Figure
3.2.2. Ibuprofen at a concentration of 5 µM significantly reduced viability and 1
and 5 µM ibuprofen significantly increased necrosis as compared with 0 µM
ibuprofen. Viability was not significantly different between 0 µM ibuprofen and 1
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Figure 3.2.1. Schematic of the major pathways involved in arachidonic acid
metabolism and inhibitors of the various enzymes involved.
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Figure 3.2.2. Effects of ibuprofen (COX 1 and 2 inhibitor) on viability, apoptosis,
and necrosis of AA-treated HL-60 cells after 12-hour incubation.1,2
* For a given variable, value different from control (P<0.05)
** For a given variable, value different from control (P<0.01)
1
Mean ± SE of the % of control for viability, apoptosis and necrosis as measured using flow
cytometry with propidium iodide and annexin V-FITC staining.
2
HL-60 cells were pretreated with 50 µM AA.
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µM ibuprofen. Apoptosis was not significantly different between 0 µM ibuprofen
and 1, 5, and 10 µM ibuprofen. Ibuprofen at a concentration of 10 µM had no
effect as compared with 0 µM ibuprofen on HL-60 cell viability, apoptosis, and
necrosis after 12-hour incubation.
The effect of various concentrations of NDGA (5, 12, and 15-lipoxygenase
inhibitor) on viability, apoptosis, and necrosis in AA (50 µM) treated HL-60 cells
are shown in Figure 3.2.3. NDGA at a concentration of 1 µM did not significantly
differ from 0 µM NDGA for viability, apoptosis, and necrosis. NDGA at a
concentration of 5 µM significantly reduced viability and significantly increased
apoptosis when compared with 0 µM NDGA. NDGA at a concentration of 5 µM
had no significant effect on necrosis. NDGA at a concentration of 10 µM
significantly increased apoptosis and necrosis as well as significantly reduced
viability when compared with 0 µM NDGA in AA treated HL-60 cells after 12-hour
incubation.
The effects of various concentrations of baicalein (12-lipoxygenase
inhibitor) on viability, apoptosis, and necrosis on AA (50 µM) treated HL-60 cells
are shown in Figure 3.2.4. Baicalein (5 µM) significantly reduced viability and
significantly increased apoptosis and necrosis as compared with 0 µM baicalein.
Viability, apoptosis, and necrosis in AA (50 µM) treated HL-60 cells after 12-hour
incubation was not significantly different between 0, 1 and 10 µM Baicalein.
The effects of various concentrations of AA-861 (5-lipoxygenase inhibitor)
on viability, apoptosis, and necrosis in AA (50 µM) treated HL-60 cells are shown
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Figure 3.2.3. Effects of NDGA (5-, 12-, and 15-LO inhibitor) on viability,
apoptosis, and necrosis of AA-treated HL-60 cells after 12-hour incubation.1,2
* For a given variable, value different from control (P<0.05)
** For a given variable, value different from control (P<0.01)
1
Mean ± SE of the % of control for viability, apoptosis and necrosis as measured using flow
cytometry with propidium iodide and annexin V-FITC staining.
2
HL-60 cells were pretreated with 50 µM AA differ from 0 µM NDGA for viability, apoptosis, and
necrosis.
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Figure 3.2.4. Effects of baicalein (12-LO inhibitor) on viability, apoptosis, and
necrosis of AA-treated HL-60 cells after 12-hour incubation.1,2
** For a given variable, value different from control (P<0.01)
1
Mean ± SE of the % of control for viability, apoptosis and necrosis as measured using flow
cytometry with propidium iodide and annexin V-FITC staining.
2
HL-60 cells were pretreated with 50 µM AA.
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in Figure 3.2.5. AA-861 at concentrations of 1, 5 and 10 µM significantly
decreased viability as compared with 0 µM AA-861. AA-861 (1, 5, and 10 µM)
significantly increased apoptosis and necrosis as compared with 0 µM AA-861 in
AA (50 µM) treated HL-60 cells after 12-hour incubation.
The effects of MK-886 (5-lipoxygeanse activating protein inhibitor) on
viability, apoptosis, and necrosis in AA (50 µM) treated HL-60 cells are shown in
Figure 3.2.6. MK-886 (1 µM) did not significantly affect viability and necrosis as
compared with 0 µM MK-886. MK-886 (5 and 10 µM) significantly reduced
viability and significantly increased necrosis as compared with 0 µM MK-886.
MK-886 (1, 5, and 10 µM) significantly increased apoptosis as compared with 0
µM MK-886 in AA (50 µM) treated HL-60 cells after 12-hour incubation.
The effects of the various enzyme inhibitors tested on whole DNA
fragmentation of AA (50 µM) treated HL-60 cells are shown in Figure 3.2.7.
There was visible banding of multimers of 180-200 base pairs with 10 µM NDGA,
AA-861, and MK-886 at 12 hours. Baicalein (10 µM) caused DNA fragmentation
although it is not as obvious as the other inhibitors. Ibuprofen (10 µM) caused no
visible DNA fragmentation at 12 hours in AA (50 µM) treated HL-60 cells.
The effects of various enzyme inhibitors tested on a TUNEL assay of AA
(50 µM) treated HL-60 cells are shown in Figure 3.2.8. AA (50 µM) treated HL60 cells incubated with ibuprofen (Ibuprofen treated Panel B) exhibited a positive
TUNEL assay as indicated by green fluorescence. AA (50 µM) treated HL-60
cells incubated with NDGA, baicalein, AA-861, or MK-886 (Panels C, D, E, and
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Figure 3.2.5. Effects of AA-861 (5-LO inhibitor) on viability, apoptosis, and
necrosis of AA-treated HL-60 cells after 12-hour incubation.1,2
* For a given variable, value different from control (P<0.05)
** For a given variable, value different from control (P<0.01)
1
Mean ± SE of the % of control for viability, apoptosis and necrosis as measured using flow
cytometry with propidium iodide and annexin V-FITC staining.
2
HL-60 cells were pretreated with 50 µM AA.
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Figure 3.2.6. Effects of MK-886 (FLAP inhibitor) on viability, apoptosis, and
necrosis of AA-treated HL-60 cells after 12-hour incubation.1,2
* For a given variable, value different from control (P<0.05)
** For a given variable, value different from control (P<0.01)
1
Mean ± SE of the % of control for viability, apoptosis and necrosis as measured using flow
cytometry with propidium iodide and annexin V-FITC staining.
2
HL-60 cells were pretreated with 50 µM AA.

126

M

1

2

3

4

5

6

7

Figure 3.2.7. The effects of various enzyme inhibitors on whole DNA
fragmentation of AA-treated HL-60 cells after 12-hour incubation.
Lanes: M= marker lane containing a 100 bp ladder of DNA fragments from 2642 bp, 1500-100 bp;
1 = negative control (50 µM AA); 2 = Positive control (5 µM CAM); 3 = 50 µM AA + 10 µM
ibuprofen; 4 = 50 µM AA + 10 µM NDGA; 5 = 50 µM AA + 10 µM baicalein; 6 = 50 µM AA + 10
µM AA-861; 7 = 50 µM AA + 10 µM MK-886.
Gel: 1.5 % agarose gel.
Running conditions: 200 minutes at 35 volts in 1X TAE buffer.
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Figure 3.2.8. The effects of various enzyme inhibitors on TUNEL assay of AAtreated HL-60 cells after 12-hour incubation.1
A. Negative control; B. 50 µM AA + 10 µM Ibuprofen; C. 50 µM AA + 10 µM NDGA; D. 50 µM AA
+ 10 µM Baicalein; E. 50 µM AA + 10 µM AA-861; F. 50 µM AA + 10 µM MK-886
1
Positive TUNEL indicated by green fluorescence; all photos 400x.
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F, respectively) all exhibited a positive TUNEL assay indicating that apoptotic
cells are present.

Discussion:
This study shows that inhibitors of lipoxygenase enzymes increase apoptosis in
HL-60 cells treated with arachidonic acid (AA). The effect of lipoxygenase and
cyclooxygenase inhibitors on cellular apoptosis has been shown to both inhibit
and induce apoptosis depending on the cell type [9;18-21]. Our results are not
likely due to non-specific effects of the enzyme inhibitors since the inhibitors
alone had no significant effect on viability, apoptosis, and necrosis in HL-60 cells.
Inhibition of the lipoxygenase enzymes, particularly 5-LO, may shunt the
metabolism of AA to other pathways involved in the regulation of cellular
apoptosis. Thus, it is clear that downstream metabolic processing of AA by
lipoxygenases plays a critical role in the regulation of HL-60 cell apoptosis.
Acute respiratory distress syndrome is characterized by increased
pulmonary permeability, increased pulmonary vascular resistance, pulmonary
edema, progressive hypoxemia, and neutrophil accumulation [22;23]. The ability
to alter the fatty acid profile of cellular phospholipids by lowering AA content has
been shown to be beneficial in patients with acute inflammation such as that
seen in ARDS [7]. Enteral nutrition containing EPA and GLA have been shown
to reduce pulmonary inflammation, improve gas exchange and lung
microvascular permeability, reduce pro-inflammatory eicosanoid synthesis in
animal models of acute lung injury as well as improve clinical outcomes in
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patients with ARDS [5;7]. We recently reported that EPA and the combination of
EPA and GLA induce apoptosis in a concentration and time dependant manner
in HL-60 cells [13]. Feeding fish oil has been shown to increase EPA and reduce
AA concentrations in tissue phospholipids [10;11]. It has been shown that diets
rich is EPA attenuate some the pro-inflammatory effects of AA [6]. Dietary EPA
and GLA supplementation in humans for three weeks reduced the synthesis of
leukotrienes and did not increase the release of AA by neutrophils after
stimulation with ionophore A23187 [24]. Thus, the use of EPA and GLA in
enteral nutrition may induce apoptosis in neutrophils by reducing the amount of
AA in the cellular membranes.
HL-60 cells share many functional characteristics with peripheral blood
neutrophils such as containing azurophilic granules and are therefore considered
to be the preferred immortalized cell line for the study of human neutrophil
responses in vitro [16;25]. Human neutrophils are short lived and will under go
apoptosis in 6-12 hours in vitro. HL-60 cells are an immortal cell line and thus
are a good model for peripheral blood neutrophils [16].
Apoptosis plays a regulatory role in normal tissue homeostasis, control of
cell size populations, and resolution of inflammation [26;27]. In early apoptosis,
phosphatidylserine (PS), which is found on the inner leaflet of the cell membrane,
translocates to the outer leaflet of the cell membrane while the cell maintains full
membrane integrity [28]. We performed flow cytometry after dual-staining of HL60 cells with annexin V-FITC and propidium iodide (PI) to differentiate between
viable, apoptotic, and necrotic cells. During early apoptosis annexin V-FITC is
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unable to enter the cell and preferentially binds to externalized PS [29].
Propidium iodide binds to cellular DNA and does not pass through an intact cell
membrane. Therefore, viable cells contain neither stain, apoptotic cells stain with
only annexin V-FITC, and necrotic cells stain with both annexin V-FITC and PI
[30]. Under in vitro conditions, secondary necrotic cells have been defined to be
in the phase following apoptosis [31;32]. Thus, HL-60 cells that were dually
stained were likely due to apoptosis leading to secondary necrosis.
Internucleosomal DNA fragmentation is considered a hallmark of late
apoptosis and was used as a second indicator, in conjunction with flow
cytometry, to substantiate apoptosis. Cellular DNA is degraded in the
internucleosomal regions into double stranded DNA fragments of 180-200 base
pairs by endogenous DNAase, giving a characteristic banding upon gel
electrophoresis [33;34]. Camptothecin was used as a positive control for DNA
fragmentation because it is a potent inhibitor of topoisomerase I and induces
characteristic apoptotic DNA fragmentation in a dose dependent manner [30].
Visible DNA fragmentation of 180-200 base pairs was observed for 10 µM
NDGA, baicalein, AA-861, and MK-886 treated AA-treated HL-60 cells after 12hour incubation. No visible DNA fragmentation was observed for ibuprofen
treated (10 µM) AA-treated HL-60 cells. These data confirm the observed results
of flow cytometry.
Terminal dUTP nick end labeling (TUNEL) is technique to visualize
apoptotic DNA fragmentation. Fragmented 3’-OH termini of DNA are modified
with terminal deoxynucleotidyl transferase that catalyzes polymerization of
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nucleotides to free 3’-OH ends. These strands breaks are fluorescein-labeled
and are visualized under a fluorescence microscope [35;36]. TUNEL assay was
positive for all five enzyme inhibitors tested. Positive tests correspond with flow
cytometry and DNA laddering for NDGA, baicalein, AA-861, and MK-886. The
induction of apoptosis with the treatment of ibuprofen was apparent but minimal.
A possible explanation for the positive TUNEL assay with ibuprofen may be
because TUNEL detects DNA fragmentation over a longer time window as
compared with the detection of apoptosis by Annexin V-FITC flow cytometry [37].
Thus, the increase in secondary necrosis with ibuprofen in AA-treated HL-60
cells may have been detected as apoptosis if it were assayed at an earlier time
point via flow cytometry. However, the degree of positive TUNEL cells with
ibuprofen in AA-treated HL-60 cells was less than that for the other four enzyme
inhibitors. Thus, the likelihood that ibuprofen caused a significant increase in
apoptosis in AA-treated HL-60 cells is not likely as shown via flow cytometry and
DNA laddering.
Apoptosis in HL-60 cells followed a concentration dependent response to
the 5-, 12-, 15-lipoxygenase (NDGA), 5-lipoxygenase (AA-861), and 5lipoxygenase activating protein (MK-886) inhibitors. A substantial increase in HL60 cell necrosis is observed for the highest concentrations of these enzyme
inhibitors. This is attributed to apoptosis leading to secondary necrosis. In vitro,
secondary necrosis occurs when there is a deficiency in the downstream
phagocytosis clearance mechanism [26]. The translocation of PS to the outer
leaflet of the cell membrane is one of the means by which phagocytic
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macrophages recognize and clear apoptotic cells in vivo [38;39]. If apoptotic
cells are not cleared they continue to break down via secondary necrosis [33].
Since HL-60 cells were culture in vitro with no phagocytic macrophages in the
culture media, they degenerated via secondary necrosis.
The two major pathways in the metabolism of AA are the cyclooxygenase
(COX) and lipoxygenase (LO) pathways (Figure 3.2.1.) [40]. The
cyclooxygenase pathway consists of two primary enzymes, ubiquitously
expressed COX 1 and inducible COX 2. Cyclooxygenases 1 & 2 metabolize AA
to prostaglandin H2, which can be converted to other prostanoids, of which many
are considered pro-inflammatory [6;41]. Inhibition of COX 1 & 2 had no effect on
HL-60 cell apoptosis. However, inhibition of COX 1 & 2 increased necrosis in
AA-treated HL-60 cells. It has been shown that inhibition of COX with
indomethacin in AA-treated human neutrophils inhibited DNA fragmentation by
up to 60% [8]. Indomethacin has been shown to potentiate TNF-α induced
apoptosis in HL-60 cells by activation of peroxisome proliferator-activating
receptors (PPARs) and not due to inhibition of cyclooxygenase activity [18]. It
was also shown that ibuprofen had no effect on TNF-α induced apoptosis in HL60 cells [18].
The lipoxygenase pathway consists of three primary pathways, 5-LO, 12LO, and 15-LO (Figure 3.2.1). 5-Lipoxygenase metabolizes AA to form 5hydroperoxyeicosatetraenoic acid (5-HPETE) which is quickly reduced to 5hydroxyeicosatetraenoic acid (5-HETE) or leukotriene A4 (LTA4). LTA4 can
subsequently be converted to LTB4 or the cysteinyl leukotrienes (LTC4, LTD4,
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and LTE4) [40]. LTB4 plays a critical role in neutrophil viability and chemotaxis.
5-lipoxygenase activating protein (FLAP) is a membrane associated protein that
is critical in AA metabolism by 5-LO [42]. 5-LO and FLAP are highly expressed
in PMNs, monocytes, and macrophages [42]. The inhibition of FLAP with MK886 should produce similar cellular responses to the inhibition of 5-LO by AA-861
in AA-treated HL-60 cells. Inhibition of 5-LO with all concentrations of AA-861
reduced viability and increased apoptosis and necrosis in AA-treated HL-60 cells.
Inhibition of FLAP, by MK-886, similarly reduced viability and increased
apoptosis and necrosis in AA-treated HL-60 cells. Thus, our results indicate that
5-LO is critical for AA-treated HL-60 cell survival. Lipopolysaccharide (LPS)
increases the survival of human neutrophils, in vitro, and the inhibition of 5-LO or
FLAP decreases survival in LPS treated human neutrophils [43].
12-Lipoxygenase and 15-LO will produce the 12-HETEs and 15-HETEs,
respectively (Figure 3.2.1). 15-HETE can be further metabolized to form the
lipoxins (lipoxin A4 and lipoxin B4), which are considered important compounds in
inflammation and immunity [44]. Inhibition of 12-LO with baicalein in AA-treated
HL-60 cells reduced cell viability and increased apoptosis and necrosis.
However, baicalein at the highest concentration tested (10 µM) had no effect of
viability, apoptosis, and necrosis. It is possible that the highest concentration of
baicalein was non-specifically binding to other lipoxygenases and possibly other
enzymes. Various LO inhibitors have been shown to induce apoptosis in W256
cells which was partially inhibited by the addition of 12-HETE or 15-HETE [45].
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We conclude that the lipoxygenase and not the cyclooxygenase pathway
were involved in the regulation of apoptosis in AA-treated HL-60 cells. We used
several measures of apoptosis including, flow cytometry, DNA fragmentation and
TUNEL to substantiate our results and to show that inhibition of the
lipoxygenases, in particular 5-LO, increased apoptosis in AA-treated HL-60 cells.
The ability to alter the inflammatory cell phospholipid profile to reduce the amount
of AA available for metabolism to pro-inflammatory eicosanoids may lead to new
therapies that will increase neutrophil apoptosis and provide an injury-limiting
pathway in the resolution of pulmonary inflammation in ARDS.
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III. Inhibition of 5-Lipoxygenase Induces Cell Death in Anti-Inflammatory
Fatty Acid-Treated HL-60 Cells1
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Abstract:
Enteral nutrition containing eicosapentaenoic (20:5 n-3) and γ-linolenic acid (18:3
n-6) decreases leukotriene B4 levels and neutrophils in bronchoalveolar lavage
fluid of patients and animals with acute respiratory distress syndrome. Reduction
in pulmonary inflammation may be due to decreased neutrophil migration and/or
survival. We showed that apoptosis increases in eicosapentaenoic/γ-linolenic
acid-treated HL-60 cells. However, it is not known if eicosapentaenoic/γ-linolenic
acid induced apoptosis involves downstream metabolic products of lipoxygenase
and cyclooxygenase enzymes. This study determined the effects of inhibitors of
lipoxygenase and cyclooxygenase enzymes on eicosapentaenoic/γ-linolenic acidtreated HL-60 cells. Cells were incubated with 50µM eicosapentaenoic /20µM γlinolenic acid in the presence of an enzyme inhibitor (1-10µM) for 12 hours.
Compounds were used to inhibit cyclooxygenase (ibuprofen), 12-lipoxygenase
(baicalein), or 5-lipoxygenase (AA-861). Flow cytometry assessed viability,
apoptosis, and necrosis. 5-lipoxygenase inhibition reduced cell viability and
increased cell death (apoptosis+necrosis) in eicosapentaenoic/γ-linolenic acidtreated HL-60 cells. Inhibition of cyclooxygenase 1 and 2 and 12-lipoxygenase
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had no significant effect on cellular viability and death in eicosapentaenoic/γlinolenic acid-treated HL-60 cells. Adding leukotriene B4 counteracted the effect
of 5-lipoxygenase inhibition on apoptosis in eicosapentaenoic/γ-linolenic acidtreated HL-60 cells. These data suggest that the processing of eicosapentaenoic
and γ-linolenic acid by 5-lipoxygenase is critical to HL-60 cell survival.

Key Words: Fish oil, Apoptosis, Polyunsaturated Fatty Acids, ARDS, Neutrophil

Introduction:
Pro-inflammatory eicosanoids derived from arachidonic acid (AA, 20:4 n-6) play
an essential role in the development of septic shock, systemic inflammatory
response syndrome, acute lung injury, and acute respiratory distress syndrome
(ARDS) [1]. Enteral nutrition with diets containing polyunsaturated fatty acids
(PUFA) of the n-3 and n-6 series, eicosapentaenoic acid (EPA, 20:5 n-3) and γlinolenic acid (GLA, 18:3 n-6), respectively, have been shown to have antiinflammatory actions in vivo [2-5]. Diets supplemented with EPA and GLA
reduce arachidonic acid (AA, 20:4 n-6) and increase EPA and dihomo-γ-linolenic
acid (DGLA, 20:3 n-6) (GLA is rapidly elongated to DGLA) concentrations in
tissue and inflammatory cell membrane phospholipids [6;7] and reduce synthesis
of pro-inflammatory eicosanoids in animal models of acute lung injury [3;4]. The
ability to alter the fatty acid profile of cellular phospholipids in inflammatory cells
has been shown to be beneficial in patients with acute pulmonary inflammation
such as ARDS [3]. For example, we showed improved clinical indices of
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respiratory function and oxygenation with improved clinical outcomes in patients
with ARDS [3;4].
Dietary PUFA of the n-3 and n-6 series may also have important
therapeutic applications in the clinical management of patients with inflammatory
disorders by modulation of apoptosis and viability of inflammatory cells.
Neutrophil clearance by apoptosis is an important physiological mechanism that
limits tissue damage and promotes the resolution of inflammation [8].
Leukotriene B4 (LTB4), a downstream AA metabolite of 5-lipoxygenase (5-LO),
plays a major role in chemotaxis and is critical for prolonged neutrophil survival.
[2;4;9;10]. In the absence of the products of 5-LO, cells tend to undergo
apoptosis at a faster rate than cells exposed to 5-LO products [11;12]. The
downstream metabolites of GLA, PGE1 and 15-hydroxyeicosatriaenoic acid, have
been shown to attenuate LTB4 production by inhibiting 5-LO [13]. Leukotriene B5
(LTB5), a downstream EPA product of 5-LO, is less biologically active than its
LTB4 counterpart [4]. We showed in animal models of acute lung injury that
enteral nutrition with EPA and GLA significantly reduced LTB4 levels in
bronchoalveolar lavage fluid (BAL) and decreased pulmonary neutrophil
infiltration [4]. Our findings may be due, in part, to diminished numbers of
neutrophils in the lung due to a decrease in neutrophil chemotaxis and/or and
increase in neutrophil apoptosis.
We recently showed that EPA and the combination of EPA and GLA
significantly induced apoptosis and reduced cell viability in human promyelocytic
HL-60 cells, in vitro [14]. The HL-60 cell line is considered to be the preferred
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immortalized cell line for the study of human neutrophil responses in vitro [15;16].
HL-60 cells are an immortal human promyelocytic cell line and share many of the
same characteristics as human neutrophils such as containing azurophilic
granules [15;16]. The purpose of this study was to use this cell line as a model
of human neutrophils to determine if the downstream metabolic products of the
lipoxygenase (LO) and cyclooxygenase (COX) are involved in the induction of
cell death and reduced viability with EPA and GLA in HL-60 cells, in vitro. Our
results show that the presence of a 5-LO inhibitor caused a further increase in
cell death and a substantial reduction in cell viability in EPA and GLA treated-HL60 cells. Inhibition of 12-LO or cyclooxygenase did not have any effects on EPA
and GLA-treated HL-60 cells. Incubation with exogenous LTB4 counteracted the
effects of 5-LO inhibition in EPA and GLA-treated HL-60 cells.

Materials and Methods:
Cells. The human promyelocytic leukemia cell line HL-60 was obtained from
American Type Tissue Culture Collection (Manassas, VA). Cells were cultured in
RPMI 1640 medium with phenol red supplemented with HEPES (25 mM;
BioWhittaker, Walkersville, MD), 10 % heat inactivated fetal bovine serum, 1 %
penicillin-streptomycin solution (Sigma Chemical, St. Louis, MO), and 1 % Lglutamine (BioWhittaker, Walkersville, MD). Cells were maintained at 37°C in an
atmosphere of 5 % CO2 and 95 % room air in a NAPCO model 5410 incubator
(Precision Scientific, Chicago, IL).

Treatments.
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All chemicals and reagents were from Sigma Chemical (St. Louis,

MO) unless otherwise noted. Cell number and viability were assessed using a
hemacytometer and trypan blue dye exclusion technique. Cells were plated in
sterile Costar 6 well cell culture plates (Corning, Corning, NY) at a concentration
of 300,000 cells/ml. Cells were treated with 50 µM EPA and 20 µM GLA in the
presence of an enzyme inhibitor for 12 hours. Compounds used to inhibit
enzymes were from Biomol (Plymouth Meeting, PA). HL-60 cells were treated
with inhibitors for COX (ibuprofen [(±)-2-(4-isobutylphenyl) propionic acid]; 1, 5,
and 10 µM), 12-LO (baicalein [5,6,7-trihydroxyflavone]; 1, 5, and 10 µM), or 5-LO
(AA-861 [2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone]; 1,
5, and 10 µM). HL-60 cells were also incubated with 10 µM AA-861 and were
subsequently treated with EPA and GLA as stated above as well as with various
concentrations (0.001, 0.01, 0.1, 1.0 µM) of LTB4 (Cayman Chemical, Ann Arbor,
MI). Fatty acid treatments were conducted under yellow incandescent light.
Methanol and DMSO were used as vehicle controls and oleic acid was used as
fatty acid control. All treatments were conducted in quadruplicate.

Detection of cell viability and cell death (flow cytometry). Detection of cell viability
and cell death by flow cytometry was performed using Annexin V-FITC and
propidium iodide stains (BD Pharmingen, San Diego, CA) as previously
described [14]. Briefly, cells were washed with phosphate buffered saline
containing 0.1 % bovine serum albumin. Cells were resuspended in 100 µl of 1X
annexin V binding buffer (BD Pharmingen, San Diego, CA). Annexin V-FITC (5
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µl) and propidium iodide (10 µl) were added to each treatment in the dark. Cells
were incubated at room temperature for 15 minutes and kept in the dark. Cell
suspensions were raised to a final volume of 500 µl with 1X annexin V binding
buffer. Flow cytometry was performed using a Becton-Dickenson FACScan flow
cytometer and Cell Quest software version 1.2 (Becton-Dickenson, San Jose,
CA).

Statistics. Data are expressed as mean percent ± SE. Differences in mean
percent were determined by one-way analysis of variance followed by REGWF
mean separation to determine statistical significance. P < 0.05 was considered
significant. Data were analyzed using CRUNCH version 4.0 statistical package
(Crunch Software Corp., Oakland, CA).

Results:
The metabolism of polyunsaturated fatty acids by lipoxygenase and
cyclooxygenase enzymes can be blocked with specific enzyme inhibitors (Figure
3.3.1). Incubation of HL-60 cells in the presence of each inhibitor alone, in the
absence of exogenous fatty acids, and with oleic acid did not induce cell death
and did not affect cell viability after 12-hour incubation (Table 3.3.1).
The effect of various concentrations of AA-861, a 5-lipoxygenase inhibitor,
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Figure 3.3.1. Major pathways of polyunsaturated fatty acid metabolism and
inhibitors of key enzymes.
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Table 3.3.1. Effects of controls on cellular viability and death on HL-60 cells after
12-hour incubation.1
12-Hour Incubation
% Cell Viability
% Cell Death
a
4.62a ± 0.74
No Treatment
95.33 ± 0.77
6.93a ± 1.40
92.94a ± 1.46
Oleic Acid (70 µM)
a
4.20a ± 1.02
95.72 ± 1.02
Ibuprofen (10 µM)
4.56a ± 1.06
95.39a ± 1.08
Baicalein (10 µM)
5.05a ± 1.12
94.91a ± 1.14
AA-861 (10 µM)
a

Values within a column sharing the same superscript letter are not different (P<0.05).
Mean percent of cell population ± SE as measured using flow cytometry with propidium iodide
and annexin V-FITC staining.
1
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on cell viability and cell death in EPA/GLA treated HL-60 cells after 12-hour
incubation are shown in Figure 3.3.2A and B. Figure 3.3.2A shows that
treatment of HL-60 cells with 50 µM EPA, 20 µM GLA, and 0 µM AA-861
significantly reduced cell viability as compared with no treatment by 1.23 fold.
AA-861 at concentrations of 1, 5, and 10 µM significantly reduced cell viability in
50 µM EPA and 20 µM GLA-treated cells as compared with no treatment by 1.37,
1.70, and 1.77 fold, respectively. Additionally, AA-861 at concentrations of 5 and
10 µM further significantly reduced HL-60 cell viability in 50 µM EPA and 20 µM
GLA-treated cells as compared with 50 µM EPA, 20 µM GLA, and 0 µM AA-861
treatment by 1.38 and 1.43 fold, respectively. Figure 3.3.2B shows that
treatment of HL-60 cells with 50 µM EPA, 20 µM GLA, and 0 µM AA-861
significantly increased cell death as compared with no treatment by 4.84 fold.
AA-861 at concentrations of 1, 5, and 10 µM significantly increased cell death in
50 µM EPA and 20 µM GLA-treated cells as compared with no treatment by 6.40,
9.37, and 9.72 fold, respectively. Additionally, AA-861 at concentrations of 5 and
10 µM further significantly increased cell death in 50 µM EPA and 20 µM GLAtreated cells as compared with 50 µM EPA, 20 µM GLA, and 0 µM AA-861
treatment by 1.94 and 2.01 fold, respectively.
The effect of various concentrations of ibuprofen, a cyclooxygenase 1 and
2 inhibitor, on cell viability and cell death in EPA/GLA treated HL-60 cells after
12-hour incubation are shown in Figure 3.3.3A and B. Treatment of HL-60 cells
with 50 µM EPA, 20 µM GLA, and 0 µM ibuprofen significantly reduced viability
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Figure 3.3.2. Effects of AA-861 (5-LO inhibitor) on cell viability and cell death in
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and significantly increased cell death as compared with no treatment. However,
Ibuprofen (1, 5, and 10 µM), over a wide concentration range, had no significant
effect on cell viability and cell death in 50 µM EPA and 20 µM GLA-treated cells
as compared with 50 µM EPA, 20 µM GLA, and 0 µM ibuprofen-treated HL-60
cells after a 12-hour incubation.
The effect of various concentrations of baicalein, a 12-lipoxygenase
inhibitor, on cell viability and cell death in EPA/GLA treated HL-60 cells after 12hour incubation are shown in Figure 3.3.4A and B. Treatment of HL-60 cells with
50 µM EPA, 20 µM GLA, and 0 µM baicalein significantly reduced viability and
significantly increased cell death as compared with no treatment. However,
baicalein (1, 5, and 10 µM) had no significant effect on cell viability and cell death
in 50 µM EPA and 20 µM GLA-treated cells as compared with 50 µM EPA, 20 µM
GLA, and 0 µM baicalein-treated HL-60 cells after a 12-hour incubation.
The effect of various concentrations LTB4 and 10 µM AA-861 on cell
apoptosis in EPA/GLA treated HL-60 cells after 12-hour incubation is shown in
Figure 3.3.5. LTB4 at a concentration of 1 µM significantly reduced apoptosis in
EPA/GLA/AA-861/1µM LTB4-treated HL-60 cells as compared with EPA/GLA/AA861/0 µM LTB4-treated HL-60 cells. Furthermore, this reduction was not different
than EPA/GLA-treated HL-60 cells alone. LTB4 decreased EPA/GLA/AA-861
induced apoptosis in a concentration dependent manner.
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Discussion:
We have previously shown that EPA and GLA at the same concentrations used
in this study (50 µM EPA and 20 µM GLA) significantly increased apoptosis and
secondary necrosis and significantly reduced viability after 12-hour incubation as
assessed by flow cytometry and DNA fragmentation in HL-60 cells [14]. This
study supports those findings and shows that HL-60 cell death was increased
further in the presence of an inhibitor of 5-LO. Thus, there is an additive effect of
EPA and GLA with 5-LO inhibition in regards to HL-60 cell death. Conversely,
the inhibition of 12-LO or COX 1 and 2 did not affect cell death in EPA/GLA
treated HL-60 cells. Incubation with exogenous LTB4 counteracted the effects of
5-LO inhibition in EPA/GLA treated-HL-60 cells in a concentration dependent
manner. These results indicate that LTB4, a major downstream metabolic
product of 5-LO, is important for maintenance of cell survival and suggests that
EPA and GLA initiates cell death by a mechanism that likely involves reduced
synthesis of LTB4.
Flow cytometry after dual-staining with annexin V-FITC in combination
with propidium iodide (PI) was used to differentiate between viable, apoptotic and
secondary necrotic HL-60 cells. Viable cells do not stain with either dye,
apoptotic cells with only annexin V-FITC, and secondary necrotic cells with both
annexin V-FITC and PI. In vitro, secondary necrotic cells have been defined to
be in the phase following apoptosis [17;18]. Annexin V-FITC binds to
externalized phosphatidylserine, which prior to apoptosis is distributed on the
inner leaflet of the cell membrane. In vivo, externalized phosphatidylserine is a
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physiological marker that macrophages use to recognize and engulf apoptotic
cells before they degrade via secondary necrosis [19]. Our system consists of a
homogenous cell culture that contains no phagocytic cells. Therefore, apoptotic
cells will degrade via secondary necrosis. In this study, HL-60 cells with both
stains were taken to be due to apoptosis leading to secondary necrosis and
designated cell death. We confirmed, in previous studies, the presence of
apoptotic HL-60 cells by the use of several techniques which included flow
cytometry, DNA fragmentation, and TUNEL assay [14;20]. We have previously
shown that treatment of HL-60 cells with EPA and a combination of EPA and
GLA increases apoptosis and secondary necrosis in a time and concentration
dependent manner [14]. A reduction in viability and an increase in secondary
necrosis were demonstrated at various times between 2 and 24-hour incubation.
In addition, apoptosis remained relatively constant between 8 and 24-hours of
incubation indicating that cells were undergoing apoptosis at a relatively constant
rate and that the increase in secondary necrosis was due to apoptotic cells
continuing to degrade via necrosis.
Two of the major pathways of PUFA metabolism are the cyclooxygenase
(COX) and lipoxygenase (LO) pathways [21]. The COX pathway consists of two
primary enzymes, ubiquitously expressed COX 1 and inducible COX 2.
Cyclooxygenase 1 and 2 metabolize AA to prostaglandin H2, EPA to
prostaglandin H3, and dihomo-γ-linolenic acid (GLA is quickly elongated to
dihomo-γ-linolenic acid) to prostaglandin H1 [2;22]. Inhibition of COX 1 and 2
with ibuprofen had no effect on cell death in EPA/GLA treated HL-60 cells.
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Prostaglandin E1, a GLA metabolite of COX, has been shown attenuate LTB4
production by inhibiting 5-LO [13]. The lipoxygenase pathway consists of three
primary pathways, 5-LO, 12-LO, and 15-LO. 12-LO and 15-LO metabolizes AA
to form the 12-HETEs and 15-HETEs, respectively. 15-HETE can be
metabolized to form the lipoxins (lipoxin A4 and lipoxin B4), which are considered
important compounds in inflammation and immunity [23]. We show that inhibition
of 12-LO with baicalein had no effect on cell death in EPA/GLA-treated HL-60
cells.
5-lipoxygenase metabolizes AA to form 5-HPETE, which is quickly
reduced to 5-HETE or leukotriene A4 (LTA4). LTA4 can subsequently be
converted to LTB4 or the cysteinyl leukotrienes (LTC4, LTD4, and LTE4) [21].
EPA is converted by 5-LO to the 5 series leukotrienes: LTA5, LTB5, LTC5, LTD5,
and LTE5. Eicosanoids from the 5 series leukotrienes are less biologically active
than eicosanoids from the 4 series leukotrienes [4]. LTB4 plays a critical role in
neutrophil chemotaxis and survival [24;25]. 5-LO is highly expressed in PMNs,
macrophages, and monocytes [26]. Inhibition of 5-LO metabolism with AA-861
reduced cell viability and increased cell death in EPA/GLA treated HL-60 cells.
Thus, our results suggest that 5-LO is critical for EPA/GLA-treated HL-60 cell
survival.
We conclude that LTB4 is important for maintenance of cell survival and
suggests that incubation with EPA and GLA initiates cell death by a mechanism
that likely involves reduced synthesis of LTB4. Thus, the ability to alter the fatty
acid profile of tissues and inflammatory cells with specialized enteral diets to
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increase the amount of EPA and GLA and reduce the AA content in conjunction
with 5-LO inhibitory compounds may lead to new therapies that will increase
neutrophil apoptosis and provide an injury limiting pathway in the resolution of
inflammation in ARDS.
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IV. Regulation of Apoptosis in Eicosapentaenoic Acid Treated HL-60 Cells1

1

This manuscript has submitted for publication with co-authors Brian Daley,

Blaine Enderson, Daniel Kestler, and Michael Karlstad.

Abstract:
Neutrophil apoptosis is an important physiological process in the resolution of
pulmonary inflammation. Previous studies have shown that eicosapentaenoic
acid (EPA; 20:5 n-3) increased the rate of apoptosis in a concentration and timedependant manner in HL-60 cells. However, it is not known if the EPA induced
apoptosis involves the lipoxygenase (LO) and cyclooxygenase (COX) enzymes
and/or the downstream metabolic products of these enzymes. Thus, the objective
of this study was to determine the effect of inhibitors of LO and COX enzymes on
apoptosis, viability, and necrosis in EPA-treated HL-60 cells. Cells were
incubated with 50 µM EPA in the presence of an enzyme inhibitor (1-10 µM) for
12 hours. Compounds were used to inhibit either COX 1 and 2 (ibuprofen), 5-,
12-, 15-LO (NDGA), 12-LO (baicalein), 5-LO (AA-861), and 5-LO activating
protein (MK-886). Eicosanoid (0.001-1.0 µM) add back experiments were also
conducted; LTB4 and 5-HETE with 5-LO inhibition and 12-HETE with 12-LO
inhibition. Flow cytometry, TUNEL assay, and caspase-3 western blotting were
used to assess apoptosis. Inhibition of COX 1 and 2 had no effect on apoptosis.
Inhibition of 5-LO and 12-LO significantly increased apoptosis in EPA-treated HL60 cells. Furthermore, addition of LTB4 reduced apoptosis to levels significantly
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lower than EPA-treated HL-60 cells alone. 5-HETE and 12-HETE also lowered
apoptosis to control levels. These data indicate that inhibition of LO, particularly
5-LO, increased apoptosis in EPA-treated HL-60 cells. Furthermore, this study
clearly demonstrated that the products of the LO enzymes, particularly LTB4, are
critical in the regulation of apoptosis in EPA-treated HL-60 cells.

Key Words: Acute Respiratory Distress Syndrome (ARDS), Inflammation,
Neutrophil, Pulmonary, Fish Oil

Introduction:
The acute respiratory distress syndrome (ARDS) is characterized by an increase
in neutrophil accumulation in the airways and alveoli [1]. Pulmonary injury is
caused by the release of oxygen free radicals by activated neutrophils in ARDS
[2]. The clearance of apoptotic neutrophils by alveolar macrophages limits tissue
damage [3] and may play a critical physiologic role in the resolution of pulmonary
inflammation in acute lung injury and ARDS [4]. Serial bronchoalveolar lavage
data demonstrates a progressive decrease in lung neutrophils as ARDS patients
improve and are weaned from mechanical ventilation [1]. These findings
demonstrate a central role for neutrophils in the pathogenesis of ARDS and
suggest that interventions should be aimed at regulating the rate of neutrophil
apoptosis to resolve the inflammatory response in the lung.
Apoptosis can be induced in many cell types, including neutrophils, by in
vitro exposure to various n-3 and n-6 polyunsaturated fatty acids (PUFA)
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including eicosapentaenoic acid (EPA, 20:5 n-3), γ-linolenic acid (GLA, 18:4 n-6),
and arachidonic acid (AA, 20:4 n-6) [5-8]. Enteral nutrition with EPA and GLA
attenuate some of the pro-inflammatory effects of AA-derived eicosanoids [3;912]. Several enteral nutrition studies have demonstrated that EPA and GLA
decreased the number of neutrophils and LTB4 levels in the bronchoalveolar
lavage fluid of both patients and animals with ARDS [11;12]. EPA and GLA also
reduced pulmonary inflammation and improved clinical outcomes in patients with
ARDS [12]. These improvements may be due to fewer neutrophils in the lung,
which may be a direct result of neutrophil apoptosis induced by changes in the
leukotriene profile in the lung.
EPA is incorporated into and reduces the content of AA in cell membrane
phospholipids [13;14] and competes with AA for enzymes that produce proinflammatory eicosanoids from AA [14;15]. One of the most potent
chemoattractants for neutrophils is the AA-derived product of 5-lipoxygenase,
leukotriene (LT) B4. LTB4 also enhances the ability of neutrophils to secrete
oxygen free radicals and proteolytic enzymes [11;16]. LTB4 has also been
associated with prolonged inflammatory cell survival. In the absence of AA
derived 5-LO products, cells undergo apoptosis at a faster rate than cells
exposed to AA-derived 5-LO products [6;17]. Neutrophils exposed to
lipopolysaccharide, in vitro, have a prolonged survival which can blocked with
LTB4 receptor antagonists [18]. Parenteral nutrition with EPA has been shown to
increase leukocyte membrane and plasma phospholipid content of EPA and
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leukocyte production of LTB5 in postoperative trauma patients [19]. LTB5, an
EPA derived product of 5-lipoxygenase, is less biologically active than LTB4 [11].
Human promyelocytic HL-60 cells share many functional characteristics
with peripheral blood neutrophils, such as containing azurophilic granules, and
are therefore considered to be the preferred immortalized cell line for the study of
human neutrophil responses in vitro [20;21]. We previously showed that the rate
of apoptosis increased in a time and concentration-dependent manner in EPAtreated HL-60 cells [7]. Furthermore, studies have demonstrated that the rate of
apoptosis in significantly increased with inhibition of lipoxygenase enzymes in
AA-treated HL-60 cells [8]. However, it is not known if EPA-induced apoptosis
involves the lipoxygenase (LO) and cyclooxygenase (COX) enzymes and/or the
downstream metabolic products of these enzymes. Thus, the objective of this
study was to determine the effect of inhibitors of LO and COX enzymes on
apoptosis, viability, and necrosis in EPA-treated HL-60 cells. In addition,
eicosanoid add-back experiments were conducted to investigate products of the
lipoxygenase enzymes involved in the regulation of apoptosis in EPA-treated HL60 cells.

Materials and Methods:
Cells. The human promyelocytic leukemia cell line HL-60 was obtained from
American Type Tissue Culture Collection (Manassas, VA). Cells were cultured in
RPMI 1640 medium with phenol red supplemented with HEPES (25 mM;
BioWhittaker, Walkersville, MD), 10 % heat inactivated fetal bovine serum, 1 %
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penicillin-streptomycin solution (Sigma Chemical, St. Louis, MO), and 1 % Lglutamine (BioWhittaker, Walkersville, MD). Cells were maintained at 37°C in an
atmosphere of 5 % CO2 and 95 % room air in a NAPCO model 5410 incubator
(Precision Scientific, Chicago, IL).

Treatments.

All chemicals and reagents were from Sigma Chemical (St. Louis,

MO) unless otherwise noted. Cell number and viability were assessed using a
hemacytometer and trypan blue dye exclusion technique. Cells were plated in
sterile Costar six well cell culture plates (Corning, Corning, NY) at a
concentration of 300,000 cells/ml. Cells were treated with 50 µM EPA in the
presence of an enzyme inhibitor for 12 hours. 50 µM EPA and a 12-hour
incubation were chosen based on optimal responses in previous experiments
using HL-60 cells [7]. Compounds used to inhibit enzymes were all from Biomol
(Plymouth Meeting, PA). Each fatty acid was treated with inhibitors for COX 1
and 2 (ibuprofen [(±)-2-(4-isobutylphenyl) propionic acid]; 1, 5, and 10 µM), 5-,
12-, and 15-LO (NDGA [nodihydroguaiaretic acid]; 1, 5, and 10 µM), 12-LO
(baicalein [5,6,7-trihydroxyflavone]; 1, 5, and 10 µM), 5-LO (AA-861 [2-(12hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone]; 5, 10, and 20
µM), and 5-lipoxygeanse activating protein (MK-866; 1, 5, and 10 µM). All fatty
acid treatments were conducted under yellow incandescent light. Methanol and
DMSO were used as vehicle controls and oleic acid was used as fatty acid
control. All treatments were incubated in quadruplicate.
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Add back experiments were conducted as follows. HL-60 cells were
incubated and treated with EPA as stated above. Cells were subsequently
treated with 10 µM AA-861 and various concentrations (0.001, 0.01, 0.1 and 1.0
µM) of leukotriene B4 (Cayman Chemical, Ann Arbor, MI) and various
concentrations (0.001, 0.01, 0.1 and 1.0 µM) of 5(S)-HETE (Cayman Chemical,
Ann Arbor, MI). Eicosapentaenoic acid treated HL-60 cells were subsequently
treated with 5 µM baicalein and various concentrations (0.001, 0.01, 0.1 and 1.0
µM) of 12(S)-HETE (Cayman Chemical, Ann Arbor, MI).

Detection of apoptosis (flow cytometry). Detection of apoptosis by flow cytometry
was performed as described previously using Annexin V-FITC and propidium
iodide stains (BD Pharmingen, San Diego, CA) [8]. Flow cytometry was
performed using a Becton-Dickenson FACScan flow cytometer and Cell Quest
software version 1.2 (Becton-Dickenson, San Jose, CA).

Detection of apoptosis (TUNEL). Detection of apoptosis by TUNEL assay was
performed using the in situ death detection, fluorescein kit (Roche, Mannheim,
Germany). Approximately 20,000 cells were centrifuged at 500 rpm for 5
minutes (Cytospin3, Shandon, England). Cells were air dried and fixed with
Carson solution. Slides were rinsed twice with PBS and were incubated in
cytofix/cytoperm solution (100 µl) at 4°C for 20 minutes (Pharmagen, San Diego).
Slides were rinsed in perm/wash buffer and allowed to dry. 50 µl of TUNEL
reaction mixture (kit) was added to slides and incubated in a humidified chamber
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for 60 minutes at 37°C. Hoechst stain (100 µl) was added and the slides were
incubated for 30 minutes at 37°C. Slides were rinsed with PBS and protected
with cover slips. Slides were analyzed with an Olympus BX51 fluorescent
microscope (Olympus Optical Co., LTD., Japan) and images were captured with
a cooled Q Color 3 camera (Q Imaging, Burnaby, BC Canada).

Detection of apoptosis (caspase-3 western blot). Cells were plated in sterile
Costar six well cell culture plates (Corning, Corning, NY) at a concentration of
500,000 cells/ml. Cells were treated with 50 µM EPA in the presence of an
enzyme inhibitor (10 µM ibuprofen, 10 µM NDGA, 5 µM bacalein, 10 µM AA-861,
and 10 µM MK-886) for 12 hours. Cells were removed from plates and washed
twice with PBS. Approximately 1 x 106 cells were lysed with 1X lysis buffer (10X
= 30 mM MgCl2, 100 mM NaCl, 5% (v/v) NP-40, and 100 mM Tris-HCl pH 8.0)
plus DNase (Promega, Madison, WI), RNase (Ambion, Austin, TX), and protease
inhibitor cocktail. Cell suspensions were incubated at 37°C for 10 minutes. After
incubation 0.2 volumes of 4X loading buffer (Invitrogen, Carlsbad, CA) was
added and samples were heated at 80°C for 2 minutes. Samples were loaded
onto a 12% SDS-ployacrylamide gel (Invitrogen, Carlsbad, CA) and run at 100
volts for 120 minutes in an Invitrogen Novex mini-cell (Invitrogen, Carlsbad, CA).
Kaleidoscope prestained standard was used (Bio-Rad, Hercules, CA). After
electrophoresis gels were transferred to a transfer cage. A “sandwich” was made
with nitrocellulose and Whatmann 3mm papers (England). The transfer cage
was then immersed in transfer buffer (800 ml methanol, ddH2O to 4 liters, 9.7 g

173
Tris Base, and 57.6 g glycine) in a Hoeffer transfer apparatus (Scientific
Instruments, San Francisco, CA). Transfer was run over night at 20 volts. After
the protein has been transferred the nitrocellulose is stained with Ponceau S
stain for 5 minutes. Stain was washed off with two washes of PBS for 10
minutes. Membranes were blocked for 1 hour with gentle agitation in blocking
solution (5% (w/v) Carnation non-fat dry milk in PBS and 2% normal goat sera).
After incubation, membranes were washed with TPBS (0.5% (v/v) Tween-20
(Fisher Scientific) and PBS) for 5 minutes. Membranes were incubated with
caspase-3 (human) polyclonal antibody (Cayman Chemical, Ann Arbor, MI)
diluted (1:750) in blocking solution overnight with gentle agitation at 4°C. Normal
sera control membranes were also run using normal rabbit sera in lieu of the
primary antibody. Primary antibody (and normal rabbit sera) was removed and
membranes were washed twice with TPBS for 10 minutes with gentle agitation at
room temperature. Membranes were incubated with anti-rabbit IgG (H+L) HRP
conjugate (Promega, Madison, WI) diluted (1:2500) in blocking solution for 1 hour
with gentle agitation at room temperature. After incubation membranes were
washed twice for 10 minutes with TPBS. Membranes were rinsed once with PBS
and subsequently developed using an ECL western blotting detection kit
(Amersham Biosciences, Piscataway, NJ).

Statistics. Data are expressed as mean percent ± SE. Differences in mean
percent were determined by one-way analysis of variance followed by REGWF
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mean separation to determine statistical differences. Data were analyzed using
CRUNCH version 4.0 statistical package (Crunch Software Corp., Oakland, CA).

Results:
Oleic acid, methanol and DMSO did not induce cell death (apoptosis and
necrosis) and viability was maintained after 12-hour incubation [7;8]. Ibuprofen,
NDGA, and baicalein did not induce apoptosis and necrosis and viability was
maintained after a 12-hour incubation. AA-861 and MK-886 did not induce
apoptosis and necrosis and did not affect viability at the lower concentrations at
12 hours. However, AA-861 (20 µM) and MK-886 (10 µM) significantly reduced
viability as compared with media alone. Therefore, AA-861 (20 µM) and MK-886
(10 µM) were eliminated from the data set because they alone had effects on
viability. These results indicate that the concentrations of enzyme inhibitors used
alone had no significant effects on apoptosis, viability, and necrosis in HL-60
cells.
Polyunsaturated fatty acids can be metabolized by a variety of pathways
that can be blocked with enzyme inhibitors (Figure 3.4.1.) The effects of various
concentrations of ibuprofen, a cyclooxygenase 1 and 2 inhibitor, on viability,
apoptosis, and necrosis in EPA treated HL-60 cells are shown in Figure 3.4.2.
Treatment of HL-60 cells with 50 µM EPA (control) significantly reduced viability
and significantly increased apoptosis and necrosis as compared with basal
levels. Ibuprofen (5 µM) significantly reduced viability and increased necrosis as
compared with control. Necrosis and viability were not significantly different
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Figure 3.4.1. Schematic of the major pathways involved in the metabolism of
polyunsaturated fatty acids and inhibitors of the various metabolic enzymes
involved.
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Figure 3.4.2. Effects of ibuprofen (COX 1 and 2 inhibitor) on viability, apoptosis,
and necrosis of EPA-treated HL-60 cells after 12-hour incubation.1
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Values sharing the same superscript letter are not different (P < 0.05).
Mean ± SE of the % of control for viability, apoptosis and necrosis as measured using flow
cytometry with propidium iodide and annexin V-FITC staining.
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between control and 1 µM ibuprofen. Apoptosis was not significantly different
between control and 1, 5, and 10 µM ibuprofen after 12-hour incubation.
The effects of various concentrations of NDGA, a 5-, 12-, and 15lipoxygeanse inhibitor, on viability, apoptosis and necrosis in EPA treated HL-60
cells are shown in Figure 3.4.3. Treatment of HL-60 cells with 50 µM EPA
(control) significantly increased apoptosis as compared with basal levels. NDGA
(10 µM) significantly reduced viability and necrosis as compared with control.
Necrosis and viability were not significantly different between control and 1 and 5
µM NDGA. Apoptosis was not significantly different between control and 1, 5,
and 10 µM NDGA after 12-hour incubation.
The effects of various concentrations of baicalein, a 12-lipoxygenase
inhibitor, on viability and cell death in EPA treated HL-60 cells are shown in
Figure 3.4.4. Treatment of HL-60 cells with 50 µM EPA (control) significantly
reduced viability and significantly increased apoptosis as compared with basal
levels. Baicalein (5 µM) significantly reduced viability as compared with control.
Baicalein (1 and 10 µM) were not significantly different than control for viability.
Apoptosis was significantly increased in HL-60 cells at baicalein concentrations
of 1, 5, and 10 µM as compared with control. Necrosis was significantly different
at 5 µM baicalein as compared with control after 12-hour incubation.
The effects of various concentrations of AA-861, a 5-lipoxygenase
inhibitor, on viability and cell death in EPA treated HL-60 cells are shown in
Figure 3.4.5. Treatment of HL-60 cells with 50 µM EPA (control) significantly
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necrosis of EPA-treated HL-60 cells after 12-hour incubation.1
a,b,c

Values sharing the same superscript letter are not different (P < 0.05).
Mean ± SE of the % of control for viability, apoptosis and necrosis as measured using flow
cytometry with propidium iodide and annexin V-FITC staining.
1

180
A.

Viability

120

a
% of Control

100

b
c
d

80
60
40
20
0
BASAL
a
0 µM EPA
0 µM AA-861

B.

CONTROL
b
50 µM EPA
0 µM AA-861

50 µM
c EPA
5 µM AA-861

50 µM
d EPA
10 µM AA-861

Apoptosis

500

d

% of Control

400

c

300
200

b

100

a
0
BASAL
a
0 µM EPA
0 µM AA-861

C.

CONTROL
b
50 µM EPA
0 µM AA-861

50 µMc EPA
5 µM AA-861

50 µMd EPA
10 µM AA-861

Necrosis

700

c

% of Control

600
500
400

b

300
200
100

a

a

0
BASAL
a
0 µM EPA
0 µM AA-861

CONTROL
b
50 µM EPA
0 µM AA-861

50 µMc EPA
5 µM AA-861

50 µMd EPA
10 µM AA-861
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reduced viability and significantly increased apoptosis as compared with basal
levels. AA-861 (5 and 10 µM) significantly reduced HL-60 cell viability as
compared with control. AA-861 (5 and 10 µM) significantly increased cell death
as compared with control after 12-hour incubation.
The effects of various concentrations of MK-886, a 5-lipoxygenase
activating protein inhibitor, on viability and cell death in EPA treated HL-60 cells
are shown in figure 3.4.6. Treatment of HL-60 cells with 50 µM EPA (control)
significantly reduced viability and significantly increased apoptosis as compared
with basal levels. MK-886 (1 and 5 µM) significantly reduced HL-60 cell viability
as compared with control. MK-886 (1 and 5 µM) significantly increased
apoptosis and necrosis as compared with control after 12-hour incubation.
The effects of various enzyme inhibitors tested on a TUNEL assay of
EPA-treated HL-60 cells are shown in figure 3.4.7. EPA-treated HL-60 cells
incubated with ibuprofen, NDGA, baicalein, and AA-861 (Fig. 3.4.7C-F,
respectively) all exhibited a positive TUNEL assay, indicating the presence of
apoptotic cells.
The effects of various enzyme inhibitors on whole cell extracts western
blot analysis of celaved-caspase-3 of EPA-treated HL-60 cells are shown in
figure 3.4.8. Cleaved caspase-3 is evident in all lanes after 12-hour incubation.
Densities as a percent of negative control are shown below each lane. All
treatment groups except for AA-861 had an increase in the density of cleaved
caspase-3. At 12-hours the amount of intact cleaved caspase-3 is less than the
negative control due to continued cleavage of proteins by activated proteases for
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Figure 3.4.6. Effects of MK-886 (FLAP inhibitor) on viability, apoptosis, and
necrosis of EPA-treated HL-60 cells after 12-hour incubation.1
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Figure 3.4.7. The effects of various enzymes inhibitors on TUNEL assay of EPAtreated HL-60 cells after 12-hour incubation.1
A. Negative Control; B. Positive Control (5 µM CAM); C. 50 µM EPA plus 10 µM ibuprofen; D. 50
µM EPA plus 10 µM NDGA; E. 50 µM EPA plus 5 µM baicalein; F. 50 µM EPA plus 10 µM AA861
1
Positive TUNEL indicated by green fluorescence; All photos 400x
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Caspase-3
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Figure 3.4.8. The effects of various enzymes inhibitors on active caspase-3
western blot of EPA-treated HL-60 cells after 12-hour incubation.1
1

% of negative control listed below each lane for active caspase-3.
Lanes: 1 = Negative Control, 2 = Positive Control (5µM CAM), 3 = 50 µM EPA, 4 = 50 µM EPA
plus 10 µM Ibuprofen, 5 = 50 µM EPA plus 10 µM NDGA, 6 = 50 µM EPA plus 5 µM Baicalein, 7
= 50 µM EPA plus 10 µM AA-861.
Gel: 12 % SDS-ployacrylamide gel
Running Conditions: 120 minutes at 100 volts.
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AA-861 treated HL-60 cells.
The effects on apoptosis of various concentrations of 12hydroxyeicosatetraenoic acid (12-HETE) on 5 µM baicalein-EPA treated HL-60
cells are shown in figure 3.4.9. Apoptosis was not significantly different between
control and 1.0, 0.1, 0.01, and 0.001 µM 12-HETE after 12-hour incubation.
The effects on apoptosis of various concentrations of 5hydroxyeicosatetraenoic acid (5-HETE) on 10 µM AA-861-EPA treated HL-60
cells are shown in figure 3.4.10. Apoptosis was not significantly different
between control and 1.0, 0.1, 0.01, and 0.001 µM 5-HETE after 12-hour
incubation.
The effects on apoptosis of various concentrations of LTB4 on 10 µM AA861-EPA treated HL-60 cells are shown in figure 3.4.11. Apoptosis was not
significantly different between control and 1.0 µM LTB4 after 12-hour incubation.
LTB4 (0.1, 0.01, and 0.001 µM) significantly reduced apoptosis as compared with
control.

Discussion:
We have previously shown that treatment of HL-60 cells with eicosapentaenoic
acid (EPA; 20:5 n-3) increased apoptosis and secondary necrosis and reduced
viability in a concentration and time-dependent manner. However, it was not
known if the induction of cell death by EPA involved the eicosanoid products of 5or 12-lipoxygenase (LO) and/or cyclooxygenase 1 and 2 (COX). This study
demonstrates that the increase in apoptosis and secondary
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necrosis due to EPA was increased further with inhibitors of either 5- or 12lipoxygenase in HL-60 cells. Furthermore, eicosanoid add-back experiments
showed that inhibition of the downstream metabolic processing of EPA to 5HETE and LTB4 (by inhibition of 5-LO) and/or to a lesser extent to 12-HETE (by
inhibition of 12-LO) increased apoptosis and secondary necrosis in HL-60 cells.
The inhibition of COX 1 and 2 did not affect apoptosis in EPA treated HL-60 cells.
LTB4 is a natural inflammatory ligand, potent chemoattractant of
neutrophils, and stimulator of leukocytes adhesion to endothelial cells [22;23].
Inhibition of 5-lipoxygenase with AA-861 in EPA-treated HL-60 cells significantly
increased apoptosis and secondary necrosis as well as significantly decreased
viability. Inhibition of 5-lipoxygenase activating protein (FLAP) with MK-886
produced similar cellular responses to inhibition of 5-LO with AA-861. FLAP is a
membrane associated protein that is critical in fatty acid metabolism by 5-LO
[24]. Furthermore, adding back 5-HETE to EPA-treated HL-60 cells incubated
with AA-861 returned the rate of apoptosis to a level that was not different from
EPA-treated HL-60 cells alone (Figure 3.4.10). All concentrations of 5-HETE
tested returned apoptosis to control levels, implying that 5-HETE is an important
compound in the regulation of apoptosis in EPA-treated HL-60 cells. Adding
back LTB4 to EPA-treated HL-60 cells incubated with AA-861 had the greatest
affect on apoptosis (Figure 3.4.11). At the lower concentrations of LTB4 tested
(0.1-0.001 µM) apoptosis was significantly lower than control. This implies that
LTB4 is critical to the regulation of apoptosis in EPA-treated HL-60 cells and that
in its absence cell survival will be severely reduced. This data concurs with
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human neutrophil data in which inhibition of 5-LO or FLAP decreased cell
survival in lipopolysaccharide-treated neutrophils [18]. Thus, these results
indicate that 5-LO and its products, particularly LTB4, are critical in the regulation
of apoptosis in EPA-treated HL-60 cells.
Inhibition of 12-LO with baicalein in EPA-treated HL-60 cells reduced cell
viability and increased apoptosis and necrosis, with a significant increase in
apoptosis across all concentrations tested. When 12-HETE was added back to
EPA-treated HL-60 cells incubated with 5 µM baicalein, apoptosis is returned to a
level that is not different from EPA-treated HL-60 cells alone (Figure 3.4.9).
Baicalein (5 µM) had the greatest affect on increasing apoptosis in EPA-treated
HL-60 cells (Figure 3.4.4). However, at the highest concentration tested (10 µM)
did not differ from control for viability. It is possible that the highest concentration
of baicalein was nonspecifically binding to other lipoxygenases and possibly
other enzymes. Add back of 12-HETE, at all concentrations, returned apoptosis
to control levels. This implies that 12-HETE is an important compound in the
regulation of apoptosis in EPA-treated HL-60 cells.
The lipoxygenase pathway consists of three primary pathways: 5-LO, 12LO, and 15-LO (Figure 3.4.1). 5-lipoxygenase metabolizes AA to form 5hydroperoxyeicosatetraenoic acid (5-HPETE), which is quickly reduced to 5HETE or LTA4. LTA4 can subsequently be converted to the cysteinyl
leukotrienes: LTC4, LTD4, and LTE4 [25]. LTA4 can also be converted to LTB4.
The cysteinyl leukotrienes are known as slow-reacting substance of anaphylaxis
and are intimately involved in asthma and other hypersensitivity reactions [25].
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Cysteinyl leukotrienes increase permeability in post capillary venules, stimulate
mucus secretions, and potentiate bronchial constriction [26]. Leukotrienes
derived from EPA are far less pro-inflammatory than are leukotrienes derived
from AA. Furthermore, EPA derived leukotrienes compete for binding sites with
AA-derived leukotrienes [22]. 12-LO and 15-LO metabolize AA to form 12hydroxyeicosatetraenoic acid (12-HETE) and 15-hydroxyeicosatetraenoic acid
(15-HETE), respectively, and EPA to 12-hydroxyeicosapentaenoic acid (12HEPE) and 15-hydroxyeicosapentaenoic acid (15-HEPE), respectively. 12-LO
has been shown to be present in the skin of rats and when stimulated with
bradykinin and platelet activating factor, both potent pro-inflammatory
compounds, produced 12-HETE and hepoxilins [27]. Furthermore, 12-HETE
administered intradermally increased vascular permeability and acute
inflammation [27]. 15-HETE can be metabolized to form the lipoxins (lipoxins A4
and B4), which are considered important compounds in inflammation and
immunity [26]. Lipoxins decrease adhesion and transmigration of neutrophils and
inhibit chemotaxis induced by LTB4 and fMLP [28]. Lipoxins A5 and B5, derived
from EPA, are as biologically potent as AA-derived lipoxins A4 and B4 [29].
Flow cytometry after dual-staining with annexin V-FITC in combination
with propidium iodide (PI) was used to differentiate between viable, apoptotic and
secondary necrotic HL-60 cells. Viable cells do not stain with either dye,
apoptotic cells with only annexin V-FITC, and secondary necrotic cells with both
annexin V-FITC and PI. In vitro, secondary necrotic cells have been defined to
be in the phase following apoptosis [30;31]. Annexin V-FITC binds to
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externalized phosphatidylserine, which prior to apoptosis is distributed on the
inner leaflet of the cell membrane. In vivo, externalized phosphatidylserine is a
physiological marker that macrophages use to recognize and engulf apoptotic
cells before they degrade via secondary necrosis [32]. Our system consists of a
homogenous cell culture that contains no phagocytic cells. Therefore, apoptotic
cells will degrade via secondary necrosis. In this study, HL-60 cells with both
stains were taken to be due to apoptosis leading to secondary necrosis. We
confirmed, in previous studies, the presence of apoptotic HL-60 cells by the use
of DNA fragmentation and TUNEL assays [7;8]. Apoptosis remained relatively
constant between 8 and 24-hours of incubation indicating that cells were
undergoing apoptosis at a relatively constant rate and that the increase in
secondary necrosis was due to apoptotic cells continuing to degrade via
secondary necrosis [7].
Determination of apoptosis by terminal dUTP nick end-labeling (TUNEL)
assay is a technique that fluorescently visualizes apoptotic DNA fragmentation
[33;34]. TUNEL assay was positive in EPA-treated HL-60 cells for all four
enzyme inhibitors tested: ibuprofen, NDGA, baicalein, and AA-861. Although
treatment with ibuprofen exhibited a positive TUNEL assay, there was no change
in apoptosis in EPA-treated HL-60 cells as measured by flow cytometry. This
was most likely due to an increase in apoptosis caused by EPA and not
ibuprofen since no measurable increase in apoptosis was detected by analysis
with flow cytometry. We previously demonstrated that EPA alone will induce
apoptosis in HL-60 cells at 12-hours [7]. Furthermore, the number of apoptotic
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cells in EPA-treated HL-60 cells incubated with ibuprofen is less than the number
of apoptotic cells visible in EPA-treated HL-60 cells incubated with NDGA,
baicalein, and AA-861 (Figure 3.4.7 C-F, respectively).
This study demonstrated the pro-caspase-3 is cleaved to active caspase-3
with the treatment of EPA and various enzyme inhibitors. As stated before, all
treatment groups except for AA-861 had an increase in the density of cleaved
caspase-3. The decrease in cleaved caspase-3 is most likely due to the fact that
AA-861 induces significant amounts of apoptosis in EPA-treated HL-60 cells. At
this stage of apoptosis, the degradation of proteins, including caspase-3, is great
throughout the cell. Therefore, at 12-hours the amount of intact cleaved
caspase-3 is less than the negative control due to continued cleavage of proteins
by activated proteases for AA-861 treated HL-60 cells. Ibuprofen exhibited a
positive cleaved caspase-3 western blot. This is most likely due to the induction
of apoptosis by EPA rather than the inhibition of COX 1 and 2 by ibuprofen.
Furthermore, ibuprofen exhibited the most intense signal of all inhibitors tested
due to the fact that 12-hour incubation is an excellent time point for EPA-treated
HL-60 cells and much of the protein was still intact. Caspase stands for cysteine
aspartate-specific proteases [35] and is considered the workhorse of apoptosis.
Activation of caspases works through a caspase cascade starting with the
initiator caspases: caspase-8 and caspase-9 [36]. Caspase-8 cleaves and
activates caspase-3, -6, and -7 [36]. The most prevalent caspase in the cell is
caspase-3 [36]. Procaspase-3 (inactive caspase) exists as a 34 kDa protein.
Once procaspase-3 is cleaved it becomes active and yields a heterodimer
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consisting of p11 and p20 subunits [35]. Activated caspase-3 will cleave many
proteins such as cytoskeletal proteins and proteins involved in DNA repair such
as polyADP-ribose polymerase (PARP) [35]. Caspase-3, along with caspases-6
and -7 are referred to as the “executioner caspases” [36].
We conclude that the LO and not the COX pathways are involved in the
regulation of apoptosis in EPA-treated HL-60 cells. Several methods of
apoptosis detection were used including flow cytometry, TUNEL assay, and
activated caspase-3 western blots to substantiate the results and to show that
inhibition of LO, particularly 5-LO, increased apoptosis in EPA-treated HL-60
cells. Furthermore, this study clearly demonstrated that the products of the LO
enzymes, particularly LTB4, are critical in the regulation of apoptosis in EPAtreated HL-60 cells. This study provides a further understanding of the effects of
EPA on HL-60 cell apoptosis, at the cellular and molecular level, and suggests
that dietary intake of n-3 fatty acids may increase apoptosis in inflammatory cells,
thereby limiting neutrophil mediated tissue injury and enhancing the resolution of
acute inflammation such as that seen in acute lung injury and ARDS.
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V. Apoptotic Gene Expression in Eicosapentaenoic Acid and γ-Linolenic
Acid-Treated HL-60 Cells

Abstract:
Polyunsaturated fatty acids from the n-3 and n-6 series have been shown to
induce apoptosis in a variety of cell types as well as be beneficial in a variety of
health problems, such as arthritis and acute respiratory distress syndrome
(ARDS). We have previously shown, using HL-60 cells as a model for the
human neutrophil, that eicosapentaenoic acid (EPA, 20:5 n-3) and the
combination of EPA and γ-linolenic acid (GLA, 18:3 n-6) induce apoptosis in a
concentration- and time-dependent manner. However, we do not know the gene
profile of the EPA/GLA-induced apoptotic HL-60 cells. Thus, the objective of this
study was to determine the apoptotic gene profile of HL-60 cells treated with the
combination of EPA and GLA. HL-60 cells were incubated with 50 µM EPA and
20 µM GLA for 12 hours. Apoptotic gene profiles were assessed using GEArray
original series human apoptosis-2 gene arrays. Total RNA was extracted and
probes were synthesized with a primer mix unique for each array. Arrays were
hybridized and developed in a non-isotopic manner. Arrays were visualized
using a 16-bit CCD camera. The apoptotic gene profile for no treatment and
EPA/GLA-treated HL-60 cells after 12-hours differed from each other. When
comparing density values as a percent of control, all genes assayed were downregulated. However, comparison of the relative intensities of several genes in
the arrays differed between control and treatment groups. For example, Bad,
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Bax, and Fas were down regulated and Bax, Bcl-2, and p53 were up regulated
as compared with control. However, due to the unreliable data set no definitive
conclusions can be made. The ability to elucidate the apoptotic gene profile of
EPA/GLA-treated HL-60 cells may lead to new therapies in the induction of
neutrophil apoptosis to enhance the resolution of inflammation and reduce tissue
injury in patients with ARDS.

Key Words: Fish Oil, ARDS, Inflammation, Gene Profile, Neutrophil,
Polyunsaturated Fatty Acids

Introduction:
Polyunsaturated fatty acids (PUFA) from the n-3 and n-6 series have been
shown to induce apoptosis in a variety of cell types [1-5]. Eicosapentaenoic acid
(EPA; 20:5 n-3), found in fish oil, and γ-linolenic acid (GLA; 18:3 n-6), found in
borage, evening prime rose, and blackcurrant seed oils, have beneficial effects in
a variety of health problems such as inflammation, cardiovascular disease,
sepsis, arthritis, and acute respiratory distress syndrome (ARDS) [1;6-8]. The
beneficial aspect of EPA and GLA may be through the induction of cellular
apoptosis of the offending cell, i.e., neutrophils in ARDS.
Our laboratory has previously shown that enteral nutrition supplemented
with EPA and GLA, reduced the number of neutrophils in the bronchoalveolar
lavage fluid from patients and animals with ARDS [8;9]. We hypothesized that
this reduction in neutrophils may be a direct result of EPA- and GLA-induced
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neutrophil apoptosis. We subsequently demonstrated, using the human
promyelocytic leukemia cell line HL-60 as model for the human neutrophil, that
EPA and the combination of EPA and GLA induce apoptosis in a time- and
concentration-dependent manner in vitro [3]. Furthermore, we demonstrated that
lipoxygenase enzymes and their products are involved in the regulation of HL-60
cell apoptosis [10-12]. However, we do not know the gene profile of PUFAinduced apoptotic HL-60 cells. Recent studies of gene expression in
undifferentiated HL-60 cells has revealed the expression of mRNA for the
apoptotic genes bak, bik, bax, bad, bcl-2, bcl-x, bcl-w, bfl-1, fas, and caspases 14 and 7-10 [13]. After HL-60 cells were stimulated to differentiate, bak, blc-w, bfl1, fas, and caspase 1 and 9 were up-regulated, whereas bik, bcl-2, and caspase
2, 3, and 10 were down-regulated [13]. We hypothesize that treatment of HL-60
cells with the combination of EPA and GLA will increase the expression of proapoptotic genes and will decrease the expression of anti-apoptotic genes. Thus,
the objective of this study is to determine the apoptotic gene profile of HL-60 cells
treated with the combination of EPA and GLA.

Materials and Methods:
Cells: The human promyelocytic leukemia cell line HL-60 was obtained from
American Type Culture Collection (Manassas, VA). Cells were cultured in RPMI
1640 medium with phenol red supplemented with HEPES (25 mM;
BioWhittacker, Walkersville, MD), 10% heat-inactivated fetal bovine serum, 1%
penicillin-streptomycin solution (Sigma Chemical, St. Louis, MO), and 1% L-
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glutamine (BioWhittaker, Walkersville, MD). Cells were maintained at 37°C in an
atmosphere of 5 % CO2 and 95 % room air in a NAPCO model 5410 incubator
(Precession Scientific, Chicago, IL).

Treatments: All chemicals and reagents were from Sigma Chemical (St. Louis,
MO) unless otherwise noted. Cell number and viability were assessed using a
hemacytometer and trypan blue dye exclusion technique. Cells were plated in
sterile Costar 6 well cell culture plates (Corning, Corning, NY) at a concentration
of 1 x 107 cells/ml. Cells were treated with 50 µM EPA and 20 µM GLA. Cells
were treated for 12 hours only.

Detection of apoptotic genes: Treated cell cultures were subjected to total RNA
extraction using the RNAqueous Kit (Ambion, Austin, TX). Cells were pelleted
and washed then were subjected to lysis using the reagents and protocol
provided in the RNAqueous Kit. Samples were centrifuged through RNA
binding filters (kit) at 11,000 x g for 1 minute. RNA was eluted from the filter
using 25 µL of 2X nuclease-free dH2O heated to 70°C, followed by a brief
centrifugation. Lithium chloride precipitation was performed to remove
carbohydrates and gross DNA contamination. Briefly, RNA was mixed with 0.5
volume LiCl precipitation solution (kit) and incubated at –20°C for 30 minutes.
The solution was microcentrifuged at top speed for 15 minutes. Then pellet was
washed with ice cold 70% ethanol and recentrifuged. The pellet was raised in 25
µl TE buffer. Five microliters of total RNA was diluted in 295 µL of TE buffer in a
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quartz microcuvette and analyzed photometrically at wavelengths of 260 nm and
280 nm in a UV-160A dual beam spectrophometer (Shimadzu Corp. Kyoto,
Japan). Samples were assessed for quantity and purity. Samples falling outside
the A260/A280 ratio of 1.8-2.1 were considered to be either DNA or protein
contaminated and were re-exposed to the RNA binding and washing protocol.

Probe synthesis: Probes were synthesized using GEArray ampolabeling-LPR kit
(SuperArray Bioscience Corp., Frederick, MD). An annealing mixture was
prepared using 10 µg of total RNA, 2 µl of buffer P (kit) and adjusted to a total
volume of 20 µl with Rnase-free H2O. Samples were heated briefly to 70°C for 3
minutes in a GeneAmp 2700 PCR system (Applied Biosystems, Foster City, CA)
then cooled to 37°C for 10 minutes. RT cocktail (20 µL), which included 16 µL of
5X Nonrad-GEAlabeling buffer (Buffer BN, kit), 16 µL of Rnase-free water, 4 µL
RNAse Inhibitor (kit), and 4 µL reverse transcriptase (kit), was added to the 20 µl
of annealing mixture. This was then incubated at 37°C for 25 minutes then
heated to 85°C for 5 minutes to hydrolyze the RNA and to inactivate the reverse
transcriptase. LPR cocktail (60 µl), which included 72 µl buffer L (kit), 36 µl
buffer AF (array kit), which is a primer mix unique for each array type, 8 µl biotin16-dUTP (Boehringer Mannheim, Germany), and 4 µl DNA polymerase (kit), was
added to the 40 µl of the RT reaction mix. This was run on a thermal cycler as
follows: 85°C for 5 minutes, 30 cycles of 85°C for 1 minutes, 50°C for 1 minute,
72°C for 1 minutes, then 72°C for 5 minutes. The LPR reaction was immediately
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stopped by adding 10 µl of buffer C (kit) to the reaction and chilling on ice. cDNA
probes were denatured by heating the LPR reaction mix to 94°C for 2 minutes.

Hybridization: GEArray original series human apoptosis-2 gene arrays
(SupperArray) were prehybridized in hybridization tubes (Fisher Scientific,
Pittsburgh, PA) with 10 mL of GEAprehyb hybridization solution spiked with
sheared, heat-denatured salmon sperm DNA (Gibco-BRL, Gaithesburg, MD) to a
final concentration of 100 µg/ml at 68°C in an Isotemp® Hybridization Incubator
(Fisher Scientific) for 2 hours at 5 rpm. The entire volume of denatured probe
was added to 5 ml of warmed GEAprehyb. Following prehybridization,
GEAprehyb was discarded and 5 mL of GEAhyb hybridization buffer was added
to the membrane and hybridized overnight at 68°C and 5 rpm. Membranes were
washed, prepped, blocked, and developed according to the GEArray protocol
for non-isotopic detection.

Chemiluminescent Detection: Chemiluminescent detection of gene expression
was assessed on a FluroChem 8000 imager (Alpha Innotech, San Leandro, CA).
Expression of specific genes was measured by densitometry and normalized with
internal membrane hybridization controls by expressing the intensity of
experimental genes as a percentage intensity/density of the controls.
Experimental and control treatments were normalized and contrasted to assess
differential gene expression.
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Results:
GEArray original series human apoptosis-2 gene arrays of 50 µM EPA and 20
µM GLA treated and no treatment (control) HL-60 cells after 12-hour incubation
are shown in Figure 3.5.1. There is the clear presence of certain genes
impregnated on each of the arrays. The brightest spots in positions 5G, 6G, 7G,
8E, 8F, and 8G are internal controls of the Glyceraldehyde-3-phosphate
dehydrogenase (GADPH) gene. Beta actin (3G and 4G) is also an internal
control. pUC 18 (1G and 2G) is the negative control.
The apoptotic gene profile of EPA and GLA treated HL-60 cells after 12hour incubation is presented in Table 3.5.1. Table 3.5.1 gives a summary of the
presence and intensity of each gene impregnated on the membrane.
The apoptotic gene profile control HL-60 cells (no treatment) after 12-hour
incubation is presented in Table 3.5.2. Table 3.5.2 gives a summery of the
presence and intensity of each gene impregnated on the membrane.
Comparison of the relative apoptotic gene intensities of control and the
combination of EPA and GLA-treated HL-60 cells after 12-hour incubation are
shown in figure 3.5.3.
Percent of control for each gene in EPA and GLA treated HL-60 cells is
presented in Table 3.5.4. Genes are presented as an integrated density value
(IDV), which is the sum of all pixel values after background correction:
IDV = Σ (each pixel value-background)
Overall, all genes appear to have been down-regulated when comparing control
with treated gene arrays.
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50 µM EPA and 20 µM GLA

No Treatment (Control)

Figure 3.5.1. GEArray original series human apoptosis-2 gene arrays of 50 µM
EPA and 20 µM GLA-treated and no treatment (control) HL-60 cells after 12-hour
incubation.
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Table 3.5.1. Apoptotic gene profile of EPA and GLA-treated HL-60 cells after 12hour incubation.
50 µM EPA and 20 µM GLA-treated HL-60 cells
GEA
Gene Name
Description
Intensity1
Location
Bad
1A and 1B Bcl2-antagonist of cell death
Absent
Bax
1C and 1D Bcl2-associated X protein
Light
Bcl-2
1E and 1F
B-cell CLL/lymphoma 2
Moderate
Bcl-w
2A and 2B Bcl2-like 2
Very light
Bcl-x
2C and 2D Bcl2-like 1
Light
Caspase-1
2E and 2F
Apoptosis-related cysteine protease
Light
Caspase-10
3A and 3B Apoptosis-related cysteine protease
Absent
Caspase-3
3C and 3D Apoptosis-related cysteine protease
Absent
Caspase-5
3E and 3F
Apoptosis-related cysteine protease
Absent
Caspase-6
4A and 4B Apoptosis-related cysteine protease
Heavy
Caspase-7
4C and 4D Apoptosis-related cysteine protease
Very light
c-myc
4E and 4F
v-myc avian myelocytomatosis viral
Absent
oncogene homolog
Fas
5A and 5B Tumor necrosis receptor superfamily
Absent
Fas ligand
5C and 5D Ligand for Fas
Absent
gadd 45
5E and 5F
DNA-damage-inducible transcript 1
Very light
6A
and
6B
Homo
sapiens
growth
arrest
and
Light
gadd 45 β
DNA-damage inducible protein
iNOS
6C and 6D Inducible nitric oxide synthase
Absent
(NOS)
mdm2
6E and 6F
Mouse double minute 2, human
Very light
homolog of p53 binding protein
7A and 7B Nuclear factor of kappa light
Light
NFκB
polypeptide gene enhancer in B-cell
1
p21Waf1
7C and 7D Cyclin-dependent kinase inhibitor 1A
Very light
p53
7E and 7F
Tumor protein p53
Extremely
light
DR5
8A and 8B Homo sapiens TRAIL receptor 2
Absent
TRAIL
8C and 8D Tumor necrosis factor (ligand)
Extremely
superfamily, member 10
light
3G and 4G Beta Actin
Heavy
β-actin
GAPDH
5G, 6G, 7G, Glyceraldehyde-3-phosphate
Heavy
8E, 8G, and dehydrogenase
8F
pUC18
1G and 2G Bacterial plasmid
Absent
1

Intensity is presented as a subjective measurement.
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Table 3.5.2. Apoptotic gene profile of HL-60 cells after 12-hour incubation.
HL-60 cells (no treatment)
GEA
Gene Name
Description
Intensity1
Location
Bad
1A and 1B Bcl2-antagonist of cell death
Light
Bax
1C and 1D Bcl2-associated X protein
Very light
Bcl-2
1E and 1F
B-cell CLL/lymphoma 2
Light
Bcl-w
2A and 2B Bcl2-like 2
Light
Bcl-x
2C and 2D Bcl2-like 1
Very light
Caspase-1
2E and 2F
Apoptosis-related cysteine protease
Moderate
Caspase-10
3A and 3B Apoptosis-related cysteine protease
Light
Caspase-3
3C and 3D Apoptosis-related cysteine protease
Light
Caspase-5
3E and 3F
Apoptosis-related cysteine protease
Very light
Caspase-6
4A and 4B Apoptosis-related cysteine protease
Heavy
Caspase-7
4C and 4D Apoptosis-related cysteine protease
Extremely
light
c-myc
4E and 4F
v-myc avian myelocytomatosis viral
Absent
oncogene homolog
Fas
5A and 5B Tumor necrosis receptor superfamily
Extremely
light
Fas ligand
5C and 5D Ligand for Fas
Absent
gadd 45
5E and 5F
DNA-damage-inducible transcript 1
Moderate
6A and 6B Homo sapiens growth arrest and
Light
gadd 45 β
DNA-damage inducible protein
INOS
6C and 6D Inducible nitric oxide synthase
Absent
(NOS)
mdm2
6E and 6F
Mouse double minute 2, human
Moderate
homolog of p53 binding protein
Light
7A
and
7B
Nuclear
factor of kappa light
NFκB
polypeptide gene enhancer in B-cell
1
p21Waf1
7C and 7D Cyclin-dependent kinase inhibitor 1A
Absent
p53
7E and 7F
Tumor protein p53
Absent
DR5
8A and 8B Homo sapiens TRAIL receptor 2
Absent
TRAIL
8C and 8D Tumor necrosis factor (ligand)
Extremely
superfamily, member 10
light
3G and 4G Beta Actin
Heavy
β-actin
GAPDH
5G, 6G, 7G, Glyceraldehyde-3-phosphate
Heavy
8E, 8G, and dehydrogenase
8F
pUC18
1G and 2G Bacterial plasmid
Absent
1

Intensity is presented as a subjective measurement.
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Table 3.5.3. Relative intensities of apoptotic genes for control and EPA/GLAtreated HL-60 cells after 12-hour incubation.
EPA/GLA-treated
Control
Gene Name
GEA Location
1
Intensity1
Intensity
Bad
1A and 1B
Light
Absent
Bax
1C and 1D
Very light
Light
Bcl-2
1E and 1F
Light
Moderate
Bcl-w
2A and 2B
Light
Very light
Bcl-x
2C and 2D
Very light
Light
Caspase-1
2E and 2F
Moderate
Light
Caspase-10
3A and 3B
Light
Absent
Caspase-3
3C and 3D
Light
Absent
Caspase-5
3E and 3F
Very light
Absent
Caspase-6
4A and 4B
Heavy
Heavy
Caspase-7
4C and 4D
Extremely light
Very light
c-myc
4E and 4F
Absent
Absent
Fas
5A and 5B
Extremely light
Absent
Fas ligand
5C and 5D
Absent
Absent
gadd 45
5E and 5F
Moderate
Very light
6A and 6B
Light
Light
gadd 45 β
INOS
6C and 6D
Absent
Absent
mdm2
6E and 6F
Moderate
Very light
7A and 7B
Light
Light
NFκB
p21Waf1
7C and 7D
Absent
Very light
p53
7E and 7F
Absent
Extremely light
DR5
8A and 8B
Absent
Absent
TRAIL
8C and 8D
Extremely light
Extremely light
3G and 4G
Heavy
Heavy
β-actin
GAPDH
5-7G, 8E, 8G, and 8F
Heavy
Heavy
pUC18
1G and 2G
Absent
Absent
1

Intensity is presented as a subjective measurement.
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Table 3.5.4. Percent of control for apoptotic genes in EPA and GLA-treated HL60 cells after 12-hour incubation.
GEA
IDV1 EPA/GLA
% of Control2
Gene Name
IDV1 Control
Location
Bad
1A and 1B
5315364
2909217
54.5
Bax
1C and 1D
3580386
3002469
83.6
Bcl-2
1E and 1F
5013522
4968123
98.8
Bcl-w
2A and 2B
4871190
2939892
60.2
Bcl-x
2C and 2D
4071186
3528852
86.4
Caspase-1
2E and 2F
6186534
3425784
55.2
Caspase-10
3A and 3B
4397568
2597559
58.9
Caspase-3
3C and 3D
4579164
2384061
51.9
Caspase-5
3E and 3F
4763214
2413509
50.5
Caspase-6
4A and 4B
72329196
29349840
40.4
Caspase-7
4C and 4D
3812289
2957070
77.3
c-myc
4E and 4F
3850326
2609829
67.6
Fas
5A and 5B
4196340
2923941
69.4
Fas ligand
5C and 5D
2984064
2527620
84.4
gadd 45
5E and 5F
5202480
3153390
60.4
6A and 6B
4961988
3409833
68.5
gadd 45 β
iNOS
6C and 6D
3023328
2346024
77.3
mdm2
6E and 6F
5384076
2793879
51.7
7A and 7B
4617201
3801246
82.1
NFκB
p21Waf1
7C and 7D
2909217
2374245
81.3
p53
7E and 7F
3631920
2768112
76.0
DR5
8A and 8B
4141125
1904304
45.8
TRAIL
8C and 8D
3063819
2413509
78.5
3G and 4G
94627467
94931763
β-actin
1

IDV= Integrated Density Value
% of control is = (IDV EPA/GLA gene/IDV β-actin EPA/GLA)-(IDV control gene/IDV β-actin
control)/(IDV control gene/IDV β-actin control)*100+100
2
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Discussion:
The hypothesis of this study was that treatment of HL-60 cells with EPA and GLA
will increase the expression of pro-apoptotic genes and decrease the expression
of anti-apoptotic genes as compared with control. Table 3.5.4 shows the
integrated density value for control and EPA/GLA-treated HL-60 cells. This table
shows that all genes were down-regulated as compared with control. This may
be because HL-60 cells treated with EPA and GLA have increased rates of
apoptosis as previously shown [3]. Increased rates of apoptosis are indicative of
increased degradation of protein, DNA, RNA, and mRNA. It is possible that at
12-hours, the amount of intact mRNA, for the respective genes impregnated on
the membranes, was degraded sufficiently enough to make it appear that all the
genes had been down-regulated as compared with control when, in reality, there
was most likely less mRNA present due to degradation not down-regulation.
Control HL-60 cells showed expression of Bad, Bax, Bcl-2, Blc-w, Bcl-x,
caspases 1, 3, 5, 6, 7, and 10, Fas, gadd 45, gadd 45β, mdm2, NFκB, and
TRAIL. EPA/GLA-treated HL-60 cells showed expression of Bax, Bcl-2, Bcl-w,
Bcl-x, caspases 1, 6, and 7, gadd 45, gadd 45β, mdm2, NFκB, p21Waf1, p53,
and TRAIL. The data for control cells agrees with previous reports that
undifferentiated HL-60 cells express Bad, Bcl-2, Bcl-w, Fas, and caspases 1-4
and 7-10 [13;14]. Previous reports state that HL-60 cells have limited expression
of caspase-6 [13]. This is a direct contradiction of the data presented here in
where there was a heavy intensity of expression of caspase-6. Furthermore,
reports have shown that other leukemia cell lines, including HL-60 cells, express
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c-myc [15;16]. Our data indicates that HL-60 cells have no c-myc.
The expression of c-myc and Bcl-2 in leukemia cell lines has been linked
to sensitivity and resistance to multiplication and death to exposure to long-chain
polyunsaturated fatty acids (PUFA) [15]. Cells that express no Bcl-2 and low
levels of c-myc were resistant to death by exposure to PUFA [15]. This does not
agree with the data for our HL-60 cells. We have shown that PUFA induce
apoptosis in HL-60 cells and our HL-60 cells do not appear to express c-myc [3].
Again, this is due to the late time point at which apoptosis was measured
resulting in degraded mRNA and a loss of signal. Reports have shown that
treatment of HL-60 cells with EPA and arachidonic acid (AA) does not reduce the
levels of c-myc expression and that these fatty acids decrease proliferation and
differentiation in HL-60 cells [16]. It is thought that c-myc is essential for several,
but not all, types of apoptosis [16]. It has been demonstrated that exposure of T
lymphocytes to dihomo-γ-linolenic acid (GLA is rapidly elongated to dihomo-γlinolenic acid), EPA and AA result in a reduction of c-myc mRNA levels [17].
EPA has been shown to induce apoptosis in HL-60 cells with a decrease
in expression of Bcl-2 that is greater than the decrease in expression of Bax [18].
The data from our study show an increase in the expression of Bcl-2 as
compared with Bax in EPA/GLA-treated HL-60 cells after a 12-hour incubation.
The reason for this is yet to be determined.
HL-60 cells share many functional characteristics with peripheral blood
neutrophils, such as containing azurophilic granules, and are, therefore,
considered the preferred immortalized cell line for the study of human neutrophil

215
responses in vitro [13;19]. Human neutrophils are short lived and will undergo
apoptosis in 6-12 hours in vitro. HL-60 cells are an immortal cell line and do not
spontaneously undergo apoptosis at an accelerated rate. Thus, HL-60 cells can
be used measure induction of apoptosis by fatty acids and are a good model for
peripheral blood neutrophils [19]. However, mature neutrophils express a
different gene profile than HL-60 cells. For example, neutrophils essentially
express no Bcl-2 [13;20]. Human neutrophils do not express the pro-apoptotic
genes Bax, Bak, Bad, Bik, and Bcl-XS, or the anti-apoptotic genes Bcl-XL, and
Bcl-2 [13;20;21]. Neutrophils express the pro-apoptotic genes Bak and Bad and
the pro-apoptotic genes Bfl-a/A1 and Bcl-w [13;20]. The lack of Bcl-2 expression
may account for neutrophils short life and rapid onset of apoptosis in 6-12 hours
[13].
Human neutrophils express Fas but not Fas ligand [22]. This agrees with
data determined in this study for HL-60 cells. The fact that neutrophils express
the Fas death receptor makes neutrophils susceptible to apoptosis [22].
However, EPA/GLA-treated HL-60 cells did not express any Fas after 12-hour
incubation. This again may be due to the overall decrease in viable mRNA due
to rapid apoptosis and the mRNA levels may be below the limits of detection for
the system used. Granulocyte macrophage colony stimulating factor (GM-CSF),
which is elevated in the bronchoalveolar lavage fluid from patients with ARDS,
has been shown to reduce the rates of Fas-mediated neutrophil apoptosis
[22;23]. GM-CSF has also been shown to prevent apoptosis by the
downregulation of pro-apoptotic Bax [20]. Furthermore, granulocyte colony
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stimulating factor (G-CSF) is thought to delay neutrophil apoptosis by the
upregulation of Bcl-X [24].
Our laboratory has previously shown that EPA and the combination of
EPA and GLA induce apoptosis in HL-60 cells [3;11;12]. We demonstrated this
using a variety of techniques including flow cytometry, apoptotic DNA laddering,
TUNEL assay, and cleaved caspase-3 western blots. The EPA/GLA-treated HL60 cells expressed no caspase-3 after 12-hour incubation. However, we recently
showed, using western blotting techniques, that both pro-caspase-3 as well as
active cleaved caspase-3 are present in no treatment and EPA-treated HL-60
cells after 12-hour incubation [12]. This strengthens our argument that the
reason for the lack of expression of various pro-apoptotic genes as well as the
overall down regulation as a percent of control is due not to a true down
regulation but rather to a reduction of mRNA, via degradation caused by
apoptosis, to levels below the sensitivity of the Super Array membranes. Gene
expression at an early time point after exposure to EPA and GLA may leave
enough intact mRNA to detect reliable differences in gene expression with Super
Array membranes.
No conclusion can be made due to the unreliable data set generated in
this experiment. However, the ability to elucidate the gene profiles in the future
may enable us to develop new therapies in conjunction with dietary therapies that
target specific genes to cause in the induction of neutrophil apoptosis thereby
limiting tissue injury and resolving inflammation in patients with ARDS.
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Part 4
Conclusions
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I. Conclusions
From the experiments conducted in this dissertation it is concluded, first, that
eicosapentaenoic acid (EPA) and the combination of EPA and γ-linolenic acid
(GLA) induce apoptosis and secondary necrosis in a time- and concentrationdependent manner in human promyelocytic HL-60 cells. This dissertation has
also demonstrated that inhibitors of the lipoxygenase increase apoptosis in HL60 cells treated with arachidonic acid (AA). The inhibition of the lipoxygenase
enzymes, particularly 5-lipoxygenase, may shunt the metabolism of AA to other
pathways involved in the regulation of HL-60 cellular apoptosis. Thus,
downstream metabolic processing of AA by 5-lipoxygenase is critical in the
regulation of HL-60 cell apoptosis. This dissertation has demonstrated similar
effects when treating HL-60 cells with EPA and the combination of EPA and
GLA. HL-60 cell death (cell death is apoptosis plus secondary necrosis) was
increased in the presence of a 5-lipoxygenase inhibitor in the combination of
EPA- and GLA-treated HL-60 cells. Conversely, as compared with the AA study,
the inhibition of 12-lipoxygenase did not affect cell death in the combination of
EPA- and GLA-treated HL-60 cells. Incubation with LTB4 counteracted the
effects of 5-lipoxygenase inhibition in the combination of EPA- and GLA-treated
HL-60 cells in a concentration-dependent manner. These results indicate that
LTB4 is important for the maintenance of cell survival and suggests that the
combination of EPA and GLA initiate cell death by a mechanism that likely
involves reduced synthesis of LTB4. Furthermore, this dissertation has
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demonstrated that the increase in apoptosis and secondary necrosis induced by
EPA is increased further with inhibitors of 5- and 12-lipoxygenase in HL-60 cells.
Additionally, eicosanoid add-back experiments demonstrated that the 5lipoxygenase products 5-HETE and LTB4 and/or to a lesser extent the 12lipoxygenase product 12-HETE are critical in the regulation of apoptosis and
secondary necrosis in HL-60 cells. This study also demonstrated an increase in
the amount of cleaved caspase-3 in HL-60 cells treated with EPA; implying that
caspase-3 is involved in the apoptotic mechanisms induced by EPA. Finally, this
dissertation determined that there are differences between the apoptotic gene
profiles of no treatment and EPA/GLA-treated HL-60 cells. This indicates that
EPA has an effect at the genetic level and not just at a metabolic level when
inducing apoptosis in HL-60 cells.
This dissertation has helps to explain the observed effect of EPA and GLA
in human and animal studies of acute respiratory distress syndrome (ARDS):
i.e., that enteral nutrition with specialized diets containing EPA and GLA reduced
the number of neutrophils and reduced the levels of LTB4 in the bronchoalveolar
lavage fluid, reduced pulmonary inflammation, and improved clinical outcomes in
patients and animals with ARDS. This dissertation demonstrated that the
observed clinical results may be due to increased neutrophil apoptosis induced
by EPA and GLA. The induction of apoptosis likely occurs through a change in
the eicosanoid profile as well a genetic change. Thus, the ability to alter the
inflammatory cell phospholipids profile to reduce the amount of AA available for
metabolism to pro-inflammatory eicosanoids, in conjunction with 5-lipoxygenase
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inhibitory compounds, may lead to new therapies that will increase neutrophil
apoptosis and provide a injury-limiting pathway in the resolution of pulmonary
inflammation in ARDS.
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